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Daptomycin is a lipopeptide antibiotic that contains 13 amino acids and an N-terminally at-
tached fatty acyl residue. The antibiotic kills Gram-positive bacteria by membrane depolariza-
tion. It has long been assumed that the mode of action of daptomycin involves the formation
of oligomers on the bacterial cell membrane; however, at the outset of my studies, this had not
been experimentally demonstrated.
In the work described in this thesis, I have used fluorescence energy transfer (FRET) be-
tween native daptomycin and an NBD-labeled daptomycin derivative to demonstrate that the
antibiotic indeed forms oligomers on bacterial cell membranes. In a liposome model, oligomer
formation depends on calcium and on phosphatidylglycerol (PG). The oligomer forms rapidly
and is stable for a length of time longer than required for the bactericidal effect. Through vari-
ation of the ratio of FRET donor (native daptomycin) and acceptor (NBD-daptomycin), I have
determined that the oligomer consists of approximately 6–7 molecules, or, depending on the
structure of the oligomer, possibly up to twice that number.
Oligomer formation on liposomes and on bacterial membranes was confirmed using ex-
cimer fluorescence of a perylene-labeled daptomycin derivative. Excimer fluorescence was
also used to demonstrate a stoichiometric interaction between daptomycin and PG.
It has previously been shown that the bactericidal activity of daptomycin requires calcium
and correlates with the concentration of PG in the bacterial cell membrane; these requirements
mirror those observed here for oligomer formation. Furthermore, membrane permeabiliza-
tion is selective, and electron microscopy of bacterial membranes exposed to daptomycin has
revealed no discontinuities or accretions of electron density. Both of these findings suggest
formation of a small membrane lesion, which is compatible with the small size of the oligomer
that was determined here. In conjunction with these previous findings, the experiments con-
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The work described in this thesis focuses on the antibiotic daptomycin, and in particular on
the mechanism of its bactericidal action. Daptomycin is a cyclic lipopeptide antibiotic with
activity against a wide spectrum of pathogenic Gram-positive bacteria. In 2003, daptomycin
was approved by the U.S. Food and Drug Administration for the treatment of skin and skin
structure infections (see Section 1.2.4 and reference [125]).
In this chapter, I will first present a brief general overview of antibiotics and bacterial
resistance to them; this will serve to place the role and significance of daptomycin into context.
I will then turn to daptomycin itself and discuss what was known about its mode of action at the
outset of my studies. The chapter will conclude with a description of the research objectives of
my thesis.
1.1 ANTIBIOTICS
One of the most valuable and successful achievements in medicine in the 20th century was
the discovery and development of antibiotics for the treatment of bacterial infections. An-
tibiotics have saved the lives and improved the health of countless individuals. Shortly after
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their introduction, they were considered by many the “magic bullets” that would spell the end
of infectious diseases. However, these high hopes have not been fulfilled. Instead, bacterial
resistance emerged and spread, which has compromised the effectiveness of an ever greater
number of antibiotics, often to the point where those antibiotics have lost their utility for gen-
eral clinical use. The inexorable progression of resistance has led to a situation in which some
infections that once were believed to have been vanquished, have once more become difficult
to treat. Therefore, fundamental and applied research on antibiotics must continue in order to
improve their bactericidal activity and ensure their continued clinical effectiveness.
In general, antimicrobial drugs can be classified into two categories. The first one comprises
synthetic drugs, and the second natural drugs that are synthesized by microorganisms. In ad-
dition, a number of semisynthetic drugs have been developed, which are chemical derivatives
of the natural antibiotics; these derivatives usually have been optimized for more effective up-
take and increased protection from bacterial resistance mechanisms. In particular, all β -lactam
antibiotics in current clinical use are semisynthetic derivatives of natural compounds.
1.1.1 History
Throughout history, plant products were used empirically in the treatment of infectious dis-
eases; however, neither the doctors nor their patients understood the modes of action of those
therapeutic agents. In the earliest records from about 2600 BC from Mesopotamia, the use
of plant oils obtained from Cedrus (cedar) and Cupressus sempervirens (cypress) species,
Glycyrrhiza glabra (licorice), Commiphora species (myrrh), and Papaver somniferum (poppy
juice) is described. These plants are still in use to date for the treatment of illnesses ranging
from coughs and colds to parasitic infections and inflammation [29].
As described in the literature, many plants used for preparations of remedies were dried.
However, fresh ingredients (green plants) occasionally were required. For extractions, simple
or compound drugs were chopped, pounded, and pulverized, then dissolved in a liquid. Various
liquids were used alone or in combination, including water, milk, beer, wine, sesame oil, olive
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oil, and vinegar [8]. We do not know whether the choice of the solvent was made according to
observed clinical effectiveness, or rather was governed by taste.
In ancient Egypt (~1500 BC), it was observed that molds are beneficial in the treatment
of skin and wound infections; the Medical Papyri recommend the application of moldy bread
crumbs and rags to such lesions [81]. Similar recommendations are found in the Chinese
literature (Wu Shi Er Bing Fang) about the use of herbal drugs from around 1100 BC [29] and
in the Indian Ayurvedic system, which dates from about 1000 BC. The latter system was the
starting point for the primary text of Tibetan Medicine, Gyu-zhi (Four Tantras) [40]. In the
ancient Western world, it was documented that the Greeks (~300 BC) further developed the
use of herbal drugs by changing the characteristics of the used plants through cultivation [29].
While the prescriptions found in historical tradition were of course purely empirical and
were not accompanied by any notion resembling the modern concept of antibiotics, they nev-
ertheless indicated remarkable skills of observation and perception.
The modern, scientific era of antibacterial chemotherapy started in 1910. In this year, Paul
Ehrlich introduced salvarsan (arsphenamine), which has bactericidal action against the spiro-
chete Treponema pallidum, the cause of syphilis. The first synthetic drugs with activity against
a broad spectrum of bacterial pathogens were the sulfonamides. The first sulfonamide drug,
sulfamidochrysoidine, was synthesized in 1932 by two Bayer company scientists, Mietzsch
and Klarer. This compound is also a red dye and went by the trade name of “Prontosil red”
(Figure 1.1). In 1935, Gerhard Domagk observed that streptococcal infections in mice could be
treated with this dye [36, 48, 50, 17]. Intriguingly, the compound had no antibacterial activity
in vitro. This was subsequently explained by the observation that, in the metabolism of the ani-
mals’ or patients’ livers, the compound was reductively split into two components (Figure 1.1);
one of these, sulfanilamide, carried the antibacterial activity [136, 44]).1 Sulfanilamide is a
competitive inhibitor of the enzyme dihydropteroate synthetase, which uses p-aminobenzoate
as a substrate in the synthesis of dihydropteroate, an intermediate in the bacterial synthesis of



















Figure 1.1 Chemical structures of sulfamidochrysoidine (“Prontosil red”) and its active metabolite
sulfanilamide, which competes with p-aminobenzoate at the enzyme dihydropteroate synthetase
(DHPS). Inhibition of DHPS suppresses bacterial synthesis of folic acid, which causes the antibac-
terial effect of sulfanilamide.
tetrahydrofolate. Deficiency of folate inhibits the bacteria because they are dependent on their
own de novo folate synthesis. In contrast, mammals do not synthesize folic acid but instead are
able to take it up from the environment, and are thus exempt from inhibition by sulfonamides
[109]. Soon after introduction of sulfamidochrysoidine, other sulfonamide derivatives were
developed in order to improve the potency and extend activity to a wider spectrum of bacterial
species.
Penicillin was the first natural antibiotic to be discovered and isolated. It was obtained
from Penicillium notatum in 1928 by Alexander Fleming [42]. However, he could not purify
sufficient amounts for sustained clinical use. Then, in 1941, Chain and Florey demonstrated the
therapeutic usefulness of penicillin [24]; however, they initially were also unable to produce
enough penicillin for clinical use; large scale use did not start until 1943 [99].
Penicillin proved active against most Gram-positive bacteria and some Gram-negative ones,
namely Neisseria meningitidis and N. gonorrhoeae. It inhibits muramyl-transpeptidase en-
zymes that catalyze the murein transpeptidation reaction. This prevents the cross-linking of
polysaccharide chains of the bacterial cell wall peptidoglycan. As a result, the peptidoglycan
becomes mechanically weakened and is no longer able to withstand the osmotic pressure of
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the enclosed cell, which causes the cells to swell and burst [130].
Numerous other antibiotics were quickly discovered after penicillin came into use; among
the major classes of antibiotics that have been used in humans, the majority were discovered
within a time period of only around 10 years [50]. While penicillin itself is produced by a mold,
the great majority of antibiotics are obtained from soil bacteria, in particular from member
species of Streptomyces and related genera. In isolation, Streptomyces grows more slowly than
for example Bacillus or E. coli. However, by producing antibiotics that kill off susceptible
bacteria nearby, Streptomyces species are able to compete effectively in the soil; they are the
most abundant kind of soil bacteria. The antibiotics synthesized by microorganisms can be
used to control bacterial diseases in humans and animals [135].
In 1943, streptomycin was discovered by one of Waksman’s students [118]. Like penicillin,
streptomycin possesses bactericidal action; however, its mode of action is different and consists
of the quick and irreversible inhibition of ribosomal protein synthesis [87, 32]. In that period,
in 1939, R.J. Dubos discovered gramicidin [62], which is active against both Gram-positive
bacteria, except for the Gram-positive bacilli, and selected Gram-negative organisms. Gram-
icidin causes transport of sodium and potassium ions across natural and artificial membranes
[37]. Major antibiotics that were discovered shortly afterward include tetracycline and chlo-
ramphenicol, which both inhibit bacterial ribosomal protein biosynthesis and block bacterial
growth [48]. In addition to the soil, antibiotic producer microorganisms have been isolated
from other sources, such as wound infections, sewage and chicken throats [48]. It should
be noted that many, even the majority of the discovered natural antibiotics are too toxic for
therapeutic use in humans; examples are gramicidin and puromycin. However, some toxic
antibiotics, such as actinomycin D and doxorubicin, can be used in the treatment of cancer.
1.1.2 Natural and synthetic antibiotics
Antibiotics can be synthesized by microorganisms or by artificial chemical methods. Some of
the most common antibiotics are natural and used as isolated from the producing bacteria or
5
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Table 1.1 Sources of some natural antibiotics
Source microorganism Antibiotic
Bacteria
















fungi (Table 1.1). Other important chemotherapeutic antibiotics are entirely synthetic; among
those listed in Table 1.2 are sulfonamides, trimethoprim, ciprofloxacin, isoniazid, and dap-
sone. Some natural antibiotics are also produced industrially by total synthesis; an example is
chloramphenicol.
The effectiveness of antibiotics against pathogens is usually measured as the minimum
inhibitory concentration (MIC), which is the lowest concentration of antibiotic that prevents
the growth of a specific pathogen. In order for an antibiotic to be clinically effective, the MIC
has to be attainable by therapeutic dosages. Using this criterion, many antibiotics have activity
only against a narrow spectrum of pathogenic bacteria. On the other hand, broad-spectrum
antibiotics have the ability to attack many different kinds of pathogens (Table 1.2). Many
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Table 1.2 Mechanism of action of some common antibiotics.
Antibiotic Spectrum Mechanism of action
Inhibitors of cell wall synthesis
Penicillin Mostly Gram+
Penicillins and cephalosporins inhibit
transpeptidases that cross-link






Vancomycin Gram+ Binds directly to the D-Ala-D-Ala
terminus of lipid II and inhibits the
transpeptidation step
Bacitracin Gram+ Sequesters lipid carrier (bactoprenol)
that transports cell wall precursors
across the plasma membrane
Inhibition of ribosomal protein synthesis
Streptomycin Gram+, Gram-,
mycobacteria
Binds to 30S subunit, causes
misreading of mRNA
Gentamicin Gram- Binds ribosome, causes misreading
of mRNA
Chloramphenicol Gram+, Gram-, rickettsiae
and chlamydiae
Binds to 50S subunit, blocks peptide




Table 1.2 – Continued
Antibiotic Spectrum Mechanism of action
Tetracyclines Gram+, Gram-, rickettsiae
and chlamydiae




Gram+, Gram- Bind to 50S subunit and inhibit
peptide chain elongation
Nucleic acid synthesis inhibitors
Ciprofloxacin Gram+, Gram-, rickettsiae,
chlamydiae
Inhibit bacterial DNA gyrase, inhibit
replication and transcription
Rifampin Gram+, mycobacteria Inhibit DNA-dependent RNA
polymerase
Cell membrane disruption
Polymyxin B Gram- Binds and dissociates
lipopolysaccharide
Antimetabolites
Sulfonamides Gram+, Gram- Inhibit folic acid synthesis by
competing with p-aminobenzoate
Trimethoprim Gram+, Gram- Inhibition of dihydrofolate reductase
Dapsone Mycobacteria Interferes with folic acid synthesis
Isoniazid Mycobacteria Inhibits an enzyme in mycolic acid
synthesis (katG)
broad-spectrum antibiotics are obtained through semisynthesis; examples are ampicillin and
carbenicillin. Another use of semisynthesis is to combat bacterial resistance. For example,
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the spectrum of the semisynthetic antibiotic methicillin resembles that of natural penicillin;
however, the compound is stable toward β -lactamases, which are the most common resistance
mechanism of its main target pathogen, Staphylococcus aureus [113].
1.1.3 Mechanisms of action of specific antibiotics
The action modes of antibiotics differ widely; Table 1.2 summarizes the mechanisms of some
representative examples, including both natural and synthetic antibiotics.
Most of the antibiotics listed in Table 1.2 affect the synthesis of the cell wall. Such antibi-
otics typically have high therapeutic utility, since bacterial cell walls are composed of unique
structures that are not found in human or other eukaryotic cells. Another major class of ther-
apeutically useful antibiotics inhibit bacterial protein synthesis by binding to the prokaryotic
ribosome. Many of these antibiotics bind to the ribosomal RNA rather than to proteins. Some
of these antibiotics bind to the 30S subunit of the ribosome, whereas others attach to the 50S
subunit. These antibiotics cause inhibition of protein synthesis in varying steps like aminoacyl-
tRNA binding, peptide bond formation, mRNA reading, and translocation. The different activ-
ities of all these antibiotics have been instrumental in dissecting the function of the ribosome
[113].
Many translation-inhibiting antibiotics affect selectively prokaryotic organisms because the
structure of ribosomes is sufficiently different between them and humans. Thus, these com-
pounds can be used to treat bacterial infections with minimal side effects to humans. However,
puromycin, which is an aminonucleoside antibiotic obtained from Streptomyces alboniger, dis-
rupts both prokaryotic and eukaryotic protein synthesis and therefore is useful only for in vitro
research but not for therapy [111].
Antibacterial drugs that inhibit nucleic acid synthesis or damage cell membranes are usu-
ally less specific, and therefore more toxic, than the classes of antibiotics discussed above. This
is because of the similarities in nucleic acid synthetic mechanisms and also of cell membrane
structure between prokaryotes and eukaryotes. Good examples of DNA-damaging antibiotics
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are doxorubicin and bleomycin [109]. On the other hand, quinolones such as ciprofloxacin are
selective for inhibiting bacterial DNA gyrase, and are therefore widely used in medicine. In-
hibition of gyrase is toxic since it interferes with DNA replication, repair, and transcription.
Among membrane-damaging antibiotics, polymyxin binds to the lipopolysaccharide (LPS)
in the outer membrane of Gram-negative bacteria and disrupts both outer and inner bacterial
plasma membranes. LPS has no similarity to human membrane lipids, and therefore polymyxin
can be used in antibacterial therapy [113].
Antimetabolites block the functioning of metabolic pathways, often by competitively in-
hibiting biosynthetic enzymes. For example, trimethoprim inhibits folate reductase, which
catalyzes formation of both dihydrofolate and tetrahydrofolate. Trimethoprim acts synergisti-
cally with sulfonamides to inhibit folic acid metabolism. As mentioned above, humans can not
synthesize folic acid and they must obtain it in their diet, whereas the bacterial pathogens have
to synthesize their own folic acid. However, folate reductase does occur in human metabolism,
and its inhibition is highly toxic; indeed, folate reductase inhibitors such as methotrexate are
used in tumour therapy and immunosuppressive therapy. Therefore, inhibitors of microbial
folate reductase must be specific for the bacterial enzyme [109].
Another antimetabolite is isoniazid, which is used in the treatment of Mycobacterium tu-
berculosis infections (i.e., tuberculosis). Isoniazid reacts covalently with NAD. The adduct
inhibits KatG, a mycobacterial catalase/peroxidase enzyme that is involved in the synthesis of
mycolic acids, which are very long fatty acid residues found in the mycobacterial cell wall
[113].
1.1.4 Resistance to antibiotics
As discussed in Section 1.1.2, microorganisms produce natural antibiotics. Those producer or-
ganisms need to protect themselves from their own toxic products, and therefore possess spe-
cific resistance mechanisms. The genes encoding these resistance mechanisms can, in many
cases, spread between different bacterial strains by horizontal gene transfer and confer an-
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timicrobial resistance to previously susceptible species, including pathogenic ones. Clinical
application of antibiotics provides the selective pressure that causes such resistant strains to
proliferate and spread. According to the literature, “indeed there is some evidence that at least
some clinically relevant resistance genes have originated in environmental microbes” [146, 71].
The problem is compounded by the widespread use of antibiotics in farm animals, from which
the resistant bacterial strains, or the genes, can then be transmitted to humans.
In addition to horizontal gene transfer, resistance can also arise by de novo mutations; this
is obviously particularly important with synthetic antibiotics.
1.1.4.1 Resistance mechanisms. The biochemical mechanisms of resistance to antibiotics
can be divided into the following categories [109, 88]:
(1) Primary resistance. The organisms may lack the structure that an antibiotic inhibits. For
instance, Mycoplasma species lack the murein layer found in Gram-positive and Gram-negative
bacteria and therefore are naturally resistant to penicillins. Mycobacteria resist many drugs
because their cell peptidoglycan is surrounded by a dense lipid layer, which is impermeable to
most drugs.
(2) Target site alteration. In this scenario, a change in the macromolecular target of the
antibiotic—often by way of a point mutation—increases the ability of the target to discriminate
between the inhibitory antibiotic and its physiological ligand. For example, point mutations
in bacterial DNA topoisomerase II confer resistance to inhibitors such as ciprofloxacin, and
base substitutions in the 23S rRNA decrease the affinity of the ribosomes for erythromycin or
chloramphenicol.
(3) Compensatory changes in metabolism. Malaria parasites can develop resistance to the
dihydrofolate reductase inhibitor pyrimethamine through compensatory overexpression of the
enzyme [109]. In bacteria, resistance to sulfonamides may develop when they acquire the
ability to take up folic acid from the environment, circumventing the pathway that is blocked




















penicillin G benzyl-penicilloic acid
Figure 1.2 Structure of penicillin G and of benzyl-penicilloic acid, which results from its hydrolytic
cleavage by β -lactamase.
(4) Inactivation of the antibiotic by chemical modifications. For example, many staphy-
lococci produce β -lactamase, an enzyme that cleaves the β -lactam ring of most penicillins
(Figure 1.2) and cephalosporins. Antibiotics also can be inactivated by addition of new groups
to the chemical structure; this is common with aminoglycoside antibiotics, which may undergo
enzymatic acetylation or phosphorylation.
(5) Mutation of transport proteins that mediate uptake of the antibiotic. For example, point
mutations or deletion of porins may prevent permeation of antibiotics across the outer mem-
branes of Gram-negative bacteria. The uptake of fosfomycin is mediated by the glycerolphos-
phate transporter; mutations of this non-essential transporter cause development of resistance
and tend to occur rapidly.
(6) Organisms can resist antibiotics through active extrusion or efflux from the cell interior.
This process is mediated by efflux pumps. The expression of efflux pumps is often increased
by factor of >100 in multiresistant bacterial strains.
Some specific examples of bacterial resistance mechanisms that illustrate the above principles
are listed in Table 1.3.
1.1.4.2 Antibiotic-resistant pathogens. There is no doubt that the therapeutic use of an-
tibiotics generates a selective pressure that causes pathogenic bacteria to acquire resistance
mechanisms through spontaneous mutation and gene transfer, and that the spreading of resis-
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Table 1.3 Mechanisms of bacterial resistance to antibiotics (examples)
Resistance mechanism Antibiotics Microorganisms























Mutations in ribosomal RNA and proteins Streptomycin E. coli




Mutant DNA gyrase Ciprofloxacin Enterobacteriaceae
tance jeopardizes the continued effectiveness of antibiotics. The problem is made worse by
the widespread use of antibiotics in less compelling applications, such as shotgun use without
clear medical indication, as well as medication of farm animals in order to increase meat yields.
Over time, this has resulted in the emergence and spread of many highly resistant pathogenic
bacteria worldwide.
Development of resistance among pathogenic bacteria was observed almost as soon as
antibiotics had been discovered and introduced into clinical use. As an example, we can
consider staphylococci, which are Gram-positive bacteria. They are divided into two major
groups, coagulase-positive and the coagulase-negative staphylococci. Among the latter, the
most prominent species is Staphylococcus epidermidis. This bacterium inhabits the surface
of the skin and has low intrinsic pathogenicity, but is often encountered in opportunistic in-
fections of catheters and implanted devices. The most pathogenic species is Staphylococcus
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aureus, which is coagulase-positive and is commonly found on the skin and in the nasal pas-
sages of carriers [80]. S. aureus is a common cause of skin infections, abscesses, pneumonia,
and septicemia.
At the outset of the antibiotic era, almost all staphylococci were susceptible to penicillin.
However, shortly after introduction of penicillin, resistance became common, and was mostly
caused by β -lactamases. In S. aureus, resistance to penicillin had a prevalence of less than 1%
when penicillin first came into use; this figure increased to 14% in 1946, to 38% in 1947, and
finally to more than 90% today [107, 50]. The emergence of β -lactamases in staphylococci was
countered by the development of β -lactamase-resistant penicillins, such as methicillin, and of
cephalosporins. In the early 1960s, Staphylococcus aureus strains then acquired resistance to
these compounds [48]; this occurred through horizontal transfer of a gene encoding a different
muramyl-transpeptidase or penicillin-binding protein. Methicillin-resistant S. aureus (MRSA)
has since spread around the world and is now a major hospital pathogen.
With the spreading of MRSA, vancomycin became the drug of choice for treating infec-
tions by staphylococci with lacking or uncertain susceptibility to β -lactams [50]. Vancomycin
is a glycopeptide antibiotic produced by Streptomyces orientalis. It contains a peptide linked
to a disaccharide. The antibiotic blocks peptidoglycan synthesis by inhibiting the transpep-
tidation step that across-links adjacent peptidoglycan strands. It exercises this inhibition by
binding to the substrate rather than the enzyme (Figure 1.3), which is unusual. The peptide
portion of vancomycin binds to the D-alanine-D-alanine terminal sequence on the pentapep-
tide portion of peptidoglycan. For several decades, vancomycin was a reliable standby in the
treatment of antibiotic-resistant staphylococcal and enterococcal infections. However, in 1997,
vancomycin-resistant Staphylococcus aureus (VRSA) was first isolated in Japan [95]. This
finding was rapidly followed by the isolation of VRSA strains in the U.S. and other countries
[126]. VRSA emerged through horizontal gene transfer of the vanA gene from Enterococcus
faecalis [25, 60, 35]. While vancomycin-resistant staphylococci and enterococci are not yet







































Figure 1.3 Structure of vancomycin (left) and of the related glycopeptide antibiotic A82846B, bound
to its target pentapeptide moiety (shown as spheres) of lipid II [114]. Within the pentapeptide, the
terminal D-alanine residue faces upward. This residue is cleaved by muramyl-transpeptidase; its
blockade by glycopeptide antibiotics prevents transpeptidation and thus the cross-linking of murein.
(Oxygen atoms are shown in red, nitrogens in blue, and chlorine in green).
Staphylococcus aureus infections. With the fading of vancomycin, other therapeutic options
are required. Novel alternatives that have entered clinical trials or been approved for applica-
tion are linezolid, ceftobiprole, and daptomycin.
Linezolid is a member of the oxazolidinone class of drugs (Figure 1.4). It has recently been
recommended as an another choice of the treatment for some of these infections [121, 35].
Linezolid inhibits ribosomal protein synthesis at the stage of initiation [131].
Ceftobiprole is a novel broad-spectrum cephalosporin that is in phase III of clinical de-
velopment [19]. Ceftobiprole is interesting, since it seems to be the first β -lactam designed
to inhibit the penicillin-binding proteins (PBP) in MRSA [31], thus potentially restoring the



























Figure 1.4 Chemical structures of linezolid and ceftobiprole. Linezolid is a synthetic antibiotic used
for the treatment of serious infections caused by Gram-positive bacteria. Ceftobiprole is a novel
broad-spectrum cephalosporin that is in phase III of clinical development.
Daptomycin is another antibiotic that has recently been introduced into clinical use against
otherwise resistant Gram-positive pathogens [127]. Daptomycin has been widely adopted and
is currently in widespread use in North America. A few cases of resistance have been re-
ported to date [57, 85]. In addition to staphylococci, daptomycin is also used against entero-
cocci, Gram-positive bacteria [96] that are intrinsically resistant to many antibiotics including
cephalosporins, penicillin, and aminoglycosides [108]. Enterococcus faecium and E. faecalis
are the clinically most important species [137, 140]. They are a frequent cause of urinary tract
infections, bacteremia, and endocarditis, all of which can be difficult to treat due to resistance
[96]. Traditionally, only ampicillin and vancomycin were available choices in the treatment
of most cases [46]. As of 2000, resistance to ampicillin had become common, leaving van-
comycin as the sole choice for treatment [65]. Vancomycin-resistant enterococci (VRE) were
not considered as a clinical problem until recently. However, in the last few years, VRE infec-
tions have become much more frequent and emerged as a major health care problem.
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Among streptococci, the major pathogens are Streptococcus pneumoniae or pneumococcus,
Streptococcus pyogenes, and Streptococcus agalactiae. Infection with S. pneumoniae becomes
manifest mostly as respiratory disease, which is responsible for 40,000 deaths yearly in the U.S.
alone, however, this concerns mostly elderly patients [64, 106]. Around 5 million children in
the world, less than 5 years old, die each year due to pneumococcal infection [64], which,
reflects lack of access to proper nutrition and treatment more than antibiotic resistance.
Gram-negative bacteria such as gonococci and meningococci were susceptible to β -lactams
such as penicillin G. However, penicillin G is destroyed by stomach acid. Penicillin V is sim-
ilar to penicillin G, but it is more acid-resistant and can be given orally. Ampicillin can be
administered orally and possesses a broad spectrum of activity against Gram-negative bacteria
like Haemophilus influenzae, Salmonella, and Shigella. As is the case with staphylococci, re-
sistance to penicillin and ampicillin due to formation of serine-type β -lactamases has become
common. One option to overcome this resistance is through combination with β -lactamase
inhibitors; another is the use of cephalosporins such as cefotaxim, which are quite stable
to serine-type β -lactamases. However, in addition to the serine-type β -lactamases, Gram-
negative bacteria also possess metalloenzyme β -lactamases, which cleave virtually every β -
lactam antibiotic in existence [113].
In the last two decades, pathogens have been found that are resistant to almost all antibi-
otics, including all β -lactams and vancomycin. A crisis stage for antibiotics in general may be
reached [82, 13, 63, 82] if we do not find a novel antibiotics to effectively combat these widely
resistant pathogens. One novel family of antibacterial compounds are the cyclic lipopeptide
antibiotics. Among these, daptomycin is already established in clinical practice, while others
are at various stages of development [12].
1.1.5 Peptide antibiotics
Peptide antibiotics are widely considered to be potential therapeutic alternatives for infections
caused by multidrug-resistant bacteria [55, 141]. Many antibiotic peptides exhibit a lethal
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mode of action against pathogens (see reference [20] and Table 1.2), which in many cases is
mediated by permeabilization of the bacterial cell membranes.
Peptide antibiotics can be divided into two structural categories, namely cyclic and acyclic
molecules. Alamethicin and suzukacillin-A, which are produced by the fungus Trichoderma
viride, are examples of linear peptide antibiotics[103, 74], whereas tachyplesins from Tachy-
pleus tridentatus and gramicidin S from Bacillus brevis are cyclic peptides [6]. Figure 1.5
shows examples of linear and cyclic peptide antibiotics.
While the mechanisms of actions of peptide antibiotics are varying and not always fully
understood, many of them attack and permeabilize the bacterial cell membranes. Antibiotic
peptides are often cationic, and they bind to anionic lipids in the target membranes. Addition-
ally, hydrophobic interactions contribute to the peptides’ affinity for the membranes. Penetra-
tion of the head groups of the lipids unevenly distends and disrupts the membrane. Changes
to the net charge of the system may contribute to membrane destabilization [93, 147]. An ex-
ample of a synthetic cationic peptide that has entered clinical trials, for topical application in
catheter infections, is omiganan pentahydrochloride [116]. Overall, the clinical application of
such peptides is still at an early stage of development [54].
While membrane disruption through mixed electrostatic and hydrophobic interactions oc-
curs with many antibiotic peptides, one should not assume that all peptide antibiotics share this
same mode of action. For example, even lipopeptide molecules that are structurally as similar
as daptomycin and amphomycin (see Figure 1.7) have significantly different modes of action.
1.1.6 Cyclic lipopeptide antibiotics
Cyclic lipopeptide antibiotics are divided into two structural classes. The first class comprises
the cyclic lipodepsipeptides, which include at least one ester bond (−COOR−) instead of an
amide bond (−CONHR−). An example is daptomycin (Figure 1.6), which is produced by
Streptomyces roseosporus. Other cyclic depsipeptides that are structurally related to dapto-





Figure 1.5 Crystal structures of alamethicin [45] and tachyplesin [76]. Alamethicin is a linear
polypeptide ionophore antibiotic containing 20 residue containing residues of α-aminoisobutyric
acid (Aib) and a C-terminal L-phenylalaninol (Phol) unit. It adopts an α-helical structure. Tachy-
plesin is a cyclic peptide antibiotic consisting of 17 amino acid residues with a carboxyl-terminal
arginine alpha-amide. Tachyplesin I adopts a rather rigid conformation that consists mostly of β -
structure and is stabilized by two disulfide bridges.
dependent antibiotic (CDA) from Streptomyces coelicolor A [73, 104]. Figure 1.7 shows the
chemical structures of daptomycin and those related lipodepsipeptide antibiotics. Each of these
antibiotics has one or more variable positions, and the figure shows one arbitrary example for
each. All these cyclic depsipeptides have peptide rings closed by threonine, such that the ring-
closing ester bond attaches to the OH group of the threonine side chain. Daptomycin and
A54145 include three exocyclic amino acid residues, with the terminal amino group attached
to fatty acyl tail. However, CDA contains only one exocyclic amino acid residue (serine) to
which the fatty acyl tail is attached.


















































Figure 1.6 Structure of daptomycin, which is an acidic cyclic lipopeptide antibiotic containing 13
amino acids. The ten C-terminal amino acids form the cycle; the three N-terminal residues are
exocyclic. A decanoyl residue is attached to the N-terminal tryptophan.
lactams. Examples are amphomycin, which was discovered over sixty years ago [58] and is
produced by Streptomyces canus, friulimicin from Actinoplanes friuliensis, and laspartomycin
from Streptomyces viridochromogenes var. komebensis [73]. Friulimicin and laspartomycin are
also shown in Figure 1.7.
The lipopeptides amphomycin, friulimycin and laspartomycin are similar to the cyclic
lipodepsipeptides daptomycin, A54145 and CDA with respect to their acidic nature. Both
groups contain non-standard amino acids, D-amino acids, and C- and N-methylated residues
[122]; for instance, daptomycin contains the non-standard amino acids kynurenine, ornithine,
and 3-methylglutamate in addition to D-alanine, D-serine, and D-asparagine. Some positions of
amino acids in the daptomycin molecule are conserved, including aspartic acid residues Asp7






































































Figure 1.7 Chemical structures of daptomycin and of related lipopeptides and lipodepsipeptides.
Amphomycin resembles friulimicin, save for an aspartate residue that replaces asparagine in the
exocyclic position. The first three are cyclic depsipeptides, since the peptide ring is closed by an
ester bond. Daptomycin and A54145 include three exocyclic amino acid residues with terminal
amino group attached to lipid tail. In contrast, CDA contains one exocyclic amino acid residue (Ser)
liked to a shorter lipid tail. No ester bond is present in amphomycin, friulimicin, and laspartomycin,
which therefore are true cyclic lipopeptides. Each of the antibiotics has one or more variable posi-
tions, and here shows one arbitrary example for each. Dab=2,4-diaminobutyric acid, Pip=Pipecolic
acid, MeOGlu=Methoxy-glutamate, MeGlu=Methylglutamate, MeOAsp=Methoxy-aspartate.
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conserved between the daptomycin group and the amphomycin group, even though these an-
tibiotics differ in their modes of action (see below). The conserved positions are important for
antibiotic activity [73].
Despite these lipopeptide antibiotics sharing characteristic structural features with dapto-
mycin such as a lipopeptide moiety with a cyclic decapeptide core and a fatty acid tail attached
to the exocyclic amino terminus, they vary in their mechanisms of action. In particular, am-
phomycin, friulimycin, and laspartomycin inhibit the biosynthesis of membrane-bound pepti-
doglycan precursor of Gram-positive cell walls by binding to the substrate undecaprenylphos-
phate, the universal carbohydrate carrier involved in several biosynthetic pathways. In con-
trast, daptomycin and A54145 do not detectably interfere with this pathway at minimum in-
hibitory concentrations [119]. The only well-documented target molecule for daptomycin is
phosphatidylglycerol; this will be discussed in more detail in Section 1.2.3 and Chapter 2. For
CDA, no target has been characterized at the molecular level.
1.2 DAPTOMYCIN
Daptomycin is an acidic cyclic lipopeptide antibiotic that contains 13 amino acids, with a
decanoyl residue attached to the N-terminal amino group (Figure 1.6; [5, 22]). In early reports,
the molecule was referred to as LY146032. It is a member of a complex of cyclic lipopeptides
(A21978C) that share the same peptide moiety but vary with respect to the length of the N-
terminal fatty acyl tail [34]. All these lipopeptide antibiotics are obtained from Streptomyces
roseosporus [5].
Daptomycin was discovered by researchers at Eli Lilly and Company in the early 1980s. In
the late 1980s and early 1990s, Lilly conducted clinical trials for use of the drug in infections
caused by Gram-positive organisms. These early clinical trials were discontinued because
high-dose therapy caused adverse effects on skeletal muscle, including myalgia and potential
myositis [38]. The worldwide rights to daptomycin were licensed to Cubist Pharmaceuticals in
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1997, and new clinical trials with modified dosage regimens were begun in 1999. After FDA
approval in 2003, the drug came to be marketed under trade name Cubicin©.
1.2.1 Physicochemical properties
The mainly acidic nature of daptomycin and the negative net charge that prevails at neutral pH
explain its aqueous solubility. However, the decanoyl tail and the presence of several hydro-
phobic amino acid residues cause an overall amphipathic behaviour. The amphipathicity of
daptomycin is useful for purification by reversed-phase HPLC. In aqueous solution, daptomy-
cin self-associates to form micelles. 1H NMR studies at pH 6 suggest that molecular aggre-
gation takes place at concentrations in the millimolar range [9, 68]. This aggregation makes it
difficult to study the conformation of monomeric daptomycin in solution. NMR measurements
of daptomycin at 0.8 mM in the presence of excess calcium showed a binding stoichiometry of
1:1 [9].
1.2.2 Biosynthesis
Daptomycin is naturally synthesized and assembled within Streptomyces roseosporus cells by
a system of three non-ribosomal peptide synthetases (NRPSs), named DptA, DptBC, and DptD
[98, 89, 11]. Each of these synthetases contains multiple modules, each of which mediates the
recognition, activation and incorporation of one specific amino acid into the oligopeptide chain
[41]. Each module contains at least three catalytic domains: a C domain for condensation, an
A domain for activation (or adenylylation), and a T domain for thiolation.
The roles of the A and the T domain in the activation of an amino acid are illustrated in
Figure 1.8A. Once attached to the T domain, the residue awaits condensation to a preceding
residue by its cognate C domain (Figure 1.8B). The overall process starts off with the attach-
ment of the fatty acyl residue to the N-terminal tryptophan [98, 143]; it is supplied by the DptF
protein (Figure 1.8C), which in turn acquires it after adenylylation of the fatty acid by DptE
(not shown). Like other acyl carrier proteins, DptF contains a 4￿-phosphopantetheine moiety.
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Peptide synthesis proceeds in the sequence from DptA via DptBC to DptD; the C-terminal
thioesterase (TE) domain in DptD forms the lactone bond between threonine and kynurenine
and releases the molecule [73, 51]. Epimerase (E) domains in DptA and DptBC cause epimer-
ization of the initially bound L-amino acid residues to the D-forms before incorporation; this
applies to D-Asn2, D-Ala8, and D-Ser11.
Non-proteinogenic amino acids such as ornithine6, methylglutamate12, and kynurine13 are
located within the 10-amino acids macrolactone ring; these residues significantly contribute to
the bioactivity of daptomycin [105, 51].
As is the case with daptomycin, the peptide synthetases for A54145 have been molecularly
characterized, and a number of recombinant hybrids have been created in order to elucidate
structure and function and to create improved derivatives [104, 105]. This will be discussed
below.
1.2.3 Mode of action
The antibacterial activity of daptomycin is Ca2+-dependent. The antibacterial potency reaches
its maximum at a Ca2+ concentration of 1.2 mM, which is the same as the concentration of free
calcium in human extracellular fluid [14].
In early studies, Allen et al.[5] suggested that daptomycin can inhibit peptidoglycan biosyn-
thesis in Staphylococcus aureus. Daptomycin also caused leakage of K+ ions, thus causing
dissipation of the membrane potential in B. megaterium and S. aureus. These researchers sug-
gested that the cytoplasmic membrane may be the target for daptomycin and the dissipation of
membrane potential might result from its interference with the uptake of precursors for peptido-
glycan biosynthesis. However, all these observations were made at daptomycin concentrations
several times higher than the minimum inhibitory concentration (MIC), which is the lowest
concentration of an antimicrobial that will inhibit the visible growth of a microorganism after
overnight incubation; these are probably not attainable in vivo. At MIC concentrations in the








































































































































Figure 1.8 Biosynthesis of daptomycin by the Dpt non-ribosomal peptide synthesis system. For
each amino acid to be incorporated, the Dpt system contains a module with a C domain, an A
domain, a T domain, and an optional E domain, which mediate condensation, activation, thiolation,
and epimerization, respectively. A: ATP-dependent activation and thiolation of an amino acid by
the A and the T domain of the cognate module. B: A C domain attaches its cognate amino acid
to the C-terminus of the peptide that is linked to preceding T domain. C: Organization of the Dpt
system. The amino acid-conferring modules are distributed between three proteins (DptA, DptBC,
and DptD). The DptF module supplies the activated fatty acid to DptA, where it is attached to the




faecium, however, vancomycin did not [18]. The same authors also observed an inhibition of
lipoteichoic acid (LTA) biosynthesis and proposed this pathway as the target of daptomycin
[22, 18].
The proposed direct effects on macromolecular synthesis suggested by the studies cited
above could not be confirmed in more recent experiments with used concentrations of dapto-
mycin similar to MIC [119]. At low concentrations, daptomycin still causes rapid depolariza-
tion of the bacterial cell membrane [125]. Depolarization will interfere with substrate transport,
which may cause secondary disruption of macromolecular synthesis. In this context, it is also
worth noting that daptomycin is active against bacteria in the stationary phase [92]. Stationary
bacteria are not killed by β -lactams, whose established mode of action is to inhibit murein
synthesis; non-dividing bacteria do not vigorously synthesize peptidoglycan. The effect of
daptomycin on resting bacteria therefore strongly suggests a different mechanism.
As the examples of gramicidin and valinomycin show, membrane depolarization is suffi-
cient for bactericidal action, and thus the observation of depolarization in daptomycin-exposed
cells [125] would account for the bactericidal activity of daptomycin and additional effects
may contribute. L-forms of Bacillus subtilis, which are cell wall-deficient bacteria that can
grow and proliferate in osmotically stabilizing media, showed hypersensitivity to daptomycin
[145]. This provides solid evidence that the target for daptomycin is the membrane; however,
most recently, a new study has suggested that daptomycin may cause the redistribution and
functional disruption of membrane-associated enzymes, which are required in cell wall syn-
thesis and cell division, thereby affecting cell wall morphology and septation. This conclusion
was based on the colocalization of membrane-bound labeled daptomycin with the essential
cell division protein DivIVA, which correlated with cell wall and membrane defects that led
to changes in cell morphology [112]. Aberrant septation was also noted using electron mi-
croscopy [27]. Of note, that study showed no discontinuities or deformities in the lipid bilayer
as such. Daptomycin caused leakage of calcein from the bacterial cells but no entry of the
DNA-intercalating fluorescent dye ToPro3.
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In combination, the above findings suggest formation of small, discrete membrane lesions
by daptomycin. It has been proposed that such membrane lesions consist of daptomycin oligo-
mers that form after calcium-dependent membrane binding and insertion of individual dapto-
mycin molecules (Figure 1.9 [125]). Alternatively, it has been proposed that daptomycin needs
to undergo calcium-dependent oligomerization in solution in order to become competent for
membrane insertion (Figure 1.10). This hypothesis was based on the observation of daptomy-
cin oligomers or micelles in solution by NMR. This method was also used to characterize the
residues involved in the binding of calcium. In solution, daptomycin and calcium bind stoi-
chiometrically [9]. In the apo (calcium-free) structure, the four acidic residues, Asp3, Asp7,
Asp9 and MeGlu12 are not close enough to form a single Ca2+ binding site. Another study
[68] suggested that one Ca2+ binding site may be formed by Asp3 and Asp7; a second Ca2+
binding site may be involved in a second conformational change that depends on the presence
of negatively charged lipid head groups. However, this second conformational change has not
been characterized structurally [68, 61].
Due to the limited sensitivity of the method, the NMR experiments were performed at
concentrations far in excess of the MIC. They do therefore not prove that oligomerization or
micelle formation in solution indeed occurs at MIC.
Some studies on the antimicrobial activity of derivatives of daptomycin, addressed by de-
termining the minimum inhibitory concentration (MIC) in the presence of calcium, confirmed
that the methyl-group in methylglutamate (MeGlu12) and the Kyn13 residue are vital for activ-
ity [51]. To determine whether the acidic residues in daptomycin affect its bactericidal potency,
the researchers substituted all acidic side chains in daptomycin to neutral ones—Asp to Asn,
and Glu to Gln—and measured the MIC. Substitution of Asp7 and Asp9 led to complete loss
of bioactivity, whereas there were no significant effects for Asp3 and MeGlu12 on the bacte-
ricidal activity, suggesting that only conserved positions of Asp7 and Asp9 are essential for
cation binding [51, 115]. The substitution of MeGlu12 with Glu in the daptomycin molecule
structure led to a 7-fold increase in the MIC compared with the native compound and was in
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Figure 1.9 Hypothetical mechanism of daptomycin action by membrane depolarization. In the
first step, daptomycin binds to the cytoplasmic membrane in a calcium-dependent manner. It then
oligomerizes and inserts into the membrane, forming a membrane defect that releases potassium
ions and causes rapid cell death [125, 127].
full agreement with the results of Nguyen et al., likewise, the substitution of Kyn13 with Trp
increased the MIC [105].
Resistance to daptomycin is rarely reported from the Gram-positive bacteria. The only
well-characterized mechanism consists in the increased conversion of PG to lysyl-PG, which
causes partial resistance [52, 53].
Gram-negative bacteria are not susceptible to daptomycin. For example, daptomycin has
a MIC of 128 µg/ml against E. coli [104], compared with about 1 µg/ml against Gram-positive
bacteria. However, E. coli becomes susceptible to daptomycin when the outer membrane is
stripped away (J. Silverman, personal communication), indicating that daptomycin does not
depend on targets specific to the cytoplasmic membranes of Gram-positive bacteria.
In sum, the evidence suggests an important role for membrane depolarization and perme-
abilization for the bactericidal effect of daptomycin on both proliferating and resting cells.
While the formation of membrane-associated oligomers has been assumed to be involved, no
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Figure 1.10 Proposed model of the action of daptomycin in solution based on NMR studies: (a)
without calcium, daptomycin adopts a structure that is reasonably well defined but not highly am-
phiphilic. (b) At a molar ratio 1:1 calcium to daptomycin, the lipopeptide aggregates to form a
micelle or oligomer with 14–16 subunits. (c) When daptomycin oligomers approach the bacte-
rial membrane, they dissociate, and daptomycin inserts into the bilayer. Finally, bacterial cells
are killed by membrane depolarization or some other membrane-associated event [128]. Figure
adapted from reference [128].
experimental evidence was available in the literature prior to the work presented in this thesis.
1.2.4 Spectrum of Activity and Clinical Use
Daptomycin is active against a broad spectrum of Gram-positive organisms such as staphylo-
cocci and enterococci, irrespective of their resistance or susceptibility to β -lactams and van-




In 2003, the US food and Drug Administration (FDA) approved daptomycin for the treat-
ment of complicated skin and soft-tissue infections caused by various Gram-positive bacteria,
making it the first lipopeptide antibiotic to be approved for use in humans. The bactericidal
activity of daptomycin is concentration-dependent. The dosage regimen is 4 mg/kg intravenously
once per day [7, 3, 30]. Daptomycin has also been used at 6 mg/kg to treat bacteremia due to
vancomycin-resistant enterococci and right-sided infective endocarditis caused by Staphylo-
coccus aureus, including methicillin-resistant strains (MRSA) [7, 23, 108].
Advantageous characteristics of daptomycin include a long half-life of 8–9 hours [91],
which allows for once-daily dosing, as well as excellent antimicrobial activity against bacteria
with reduced glycopeptide susceptibility [1, 117]. Trials assessing the efficacy of daptomycin
in the treatment of complicated urinary tract infections are ongoing [139, 15]. Dose adjustment
is necessary in renal dysfunction to avoid adverse effects. The primary toxicity of daptomycin
is reversible dose-related myalgia and muscle weakness.
Pneumonia should not be treated by daptomycin due to the fact that daptomycin is inhibited
by pulmonary surfactant [124]. The ability to decrease the inhibition recorded by pulmonary
surfactant with maintaining the excellent antibacterial activity and low toxicity of daptomycin,
that would potentially offer a clinical candidate with extended indications, including S. pneu-
moniae pneumonia [104]. A54145E, which is similar to daptomycin in containing MeGlu12
and in its antibacterial activity, is less inhibited by surfactant [104]; however, it is more toxic
than daptomycin [28]. These observations have motivated efforts to create hybrids of the two
lipopeptides that would combine the favourable traits of both, as discussed in Section 1.2.5.
Bacterial resistance to daptomycin has been reported, although it remains rare [69]. Can-
ton et al. demonstrated daptomycin non-susceptibility (defined by the Clinical and Laboratory
Standards Institute [CLSI] as an MIC of ≥4 µg/ml for enterococci [23]) as daptomycin resis-
tance. In general, for tested strains of staphylococci and streptococci, the MIC (minimum in-
hibitory concentration) inhibiting 90% (MIC90) was from 0.25 to 0.5 µg/ml and from 2 to 4 µg/ml
for enterococcal isolates [129]. Isolates of Streptococcus pyogenes, S. agalactiae, S. dysgalac-
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tiae subsp. equisimilis and viridans streptococci are also susceptible to daptomycin in vitro
[70].
1.2.5 Structural Variation of Daptomycin
The generation of new derivatives of daptomycin is interesting both with respect to improving
activity and for elucidating the functional roles of individual amino acid residues. Such vari-
ants can be obtained 1) by semisynthesis, 2) through recombinant modification of the peptide
synthetase systems, and 3) using chemoenzymatic methods, that is, enzyme-assisted semisyn-
thesis.
Semisynthesis is essentially chemical modification of the native molecule, which can be
more or less elaborate. The most straightforward application is the modification of the single
free amino group of daptomycin, which is part of its ornithine residue. A large number of
N-acylated analogues, even ones carrying substantial substituents such as an extra tryptophan,
showed generally fairly well preserved activity, often equivalent to native daptomycin in vitro
and in vivo [59]. However, this approach has so far not resulted in improved variants.
An example of the chemoenzymatic approach is the replacement of the native N-terminally
attached fatty acyl residue. Daptomycin belongs to the A21978C complex of acidic lipopeptide
antibiotics [10, 104, 73], whose members share the same peptide portion but differ with respect
to the fatty acyl residue. This acyl portion displays a significant effect on the antibacterial
activity of the A21978C variants [33] and therefore is a logical target for further experimental
variation.
Figure 1.11 illustrates the steps of synthesis of acyl variants of daptomycin in vitro. In the
first step, the ornithine residue is protected with t-Boc. The fatty acid side chains of A21978C
can then be removed by incubation with Actinoplanes utahensis [33], or with the purified
Actinoplanes utahensis deacylase enzyme obtained from a recombinant strain of Streptomyces
lividans [75]. New analogs of A21978C can be synthesized by chemical reacylation of the
N-terminus through activation of varying acyl esters and subsequent deprotection [33, 98].
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Figure 1.11 Chemoenzymatic synthesis of daptomycin fatty acyl variants. Step (1), protection of
side chain amino group of ornithine residue in A27978C complex via tert-BOC. Step (2), enzymatic
deacylation with Actinoplanes utahensis deacylase. Step (3), reacylation of the free N-terminal
amino group with fatty acyl succinimdyl-ester and deprotection.
A series of fatty acyl derivatives were prepared and evaluated for both in vitro and in
vivo against Staphylococcus aureus and Streptococcus pyogenes; however, none of these com-
pounds, except daptomycin, could pass the clinical trials [98]. Fatty acyl derivatives have also
been prepared from A54145.
An application of the chemoenzymatic approach concerns the use of a homologous thio-
esterase to create cyclic daptomycin variants from linear peptide precursors. The thioesterase
(Te) domain is usually part of the C-terminal module in the ultimate peptide synthetase enzyme.
It has been shown, however, that the independently expressed TE domain of the Dpt system
(see section 1.2.2), or those of homologous non-ribosomal peptide synthetases, can catalyze
the cyclization of synthetic linear thioester precursors and of variants thereof. This has been
exploited to generate several daptomycin derivatives [73, 51].
Another chemoenzymatic study focused on the creation of daptomycin and A54145 hy-
brid molecules through enzymatic cyclization of the linear thioesters by the TE domains from
A54145 and daptomycin NRPSs [73]. Structure-activity relationship (SAR) studies were car-
ried out with a set of acidic lipopeptide variants of daptomycin, CDA, and A54145, containing
an alternative macrolactam. Hybrid molecules including an exocyclic daptomycin peptide and
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endocyclic A54145 peptide cores exhibited similar MICs, thus illustrating the potential for
constructing structural hybrids[115].
Several studies have created hybrids of daptomycin and A54145 using recombinant DNA
techniques. By replacing the entire DptD synthetase (see Section 1.2.2) with the homologous
enzymes from the producer strains of A54145 or CDA, hybrid lipopeptides were created that
contained Ile13 or Trp13 instead of Kyn13 [97, 26, 105]. A subsequent study reported hybrid
lipopeptides of daptomycin and A54145 with modifications by exchanging individual amino
acid residues at various positions throughout the peptide sequence [104]. The goal of that study
was to identify variants that would combine the favourably low toxicity of daptomycin with the
resistance to inhibition by lung surfactant displayed by A54145. Reportedly, one variant with
the desired profile was indeed obtained, although ultimately none of the variants has so far
entered clinical trials.
It is worth noting that, in the latter study, variants differed in biosynthetic yield by up to
almost three orders of magnitude. It seems likely that individual modules have evolved toward
cooperation with specific neighbor modules, and not all substitutions are therefore tolerated
equally well. The recombinant engineering approach therefore is not as general and straight-




As it has been pointed out in the foregoing, that the only target for daptomycin supported by
solid evidence is the membrane; there is no unequivocal evidence for any damage to the cell
that does not follow from membrane depolarization. Therefore, studies with model membranes
seem promising and relevant. I wanted to address the following open questions about the
characterization of mechanism of action of daptomycin on artificial and bacterial membranes:
1. Oligomerization of daptomycin molecules on membranes has been postulated, but no ex-
perimental evidence had been reported at the outset of this study. Therefore, the decision
to determine whether or not oligomer formation occurs on liposomes and on bacterial
cells has been made.
2. If daptomycin can oligomerize on membranes, what are the roles of specific lipids in
the daptomycin binding and oligomer formation, and how does the lipid composition
correlate with daptomycin bactericidal activity?
3. Oligomerization of daptomycin in solution had been shown by NMR at concentrations
far above the MIC; therefore, the functional significance of these oligomers is uncer-
tain. We tried to determine whether or not daptomycin forms oligomers in solution at
physiological concentrations.
Our studies were conducted using techniques that monitor fluorescence, which is signif-
icantly more sensitive than NMR and permits daptomycin molecules to be observed under
conditions and concentrations similar to MIC on both model liposomes and bacterial cells.
This approach enabled us to gain novel insights into the mode of action of daptomycin.
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Oligomerization of daptomycin on membranes
2.1 INTRODUCTION
Daptomycin is a lipopeptide antibiotic produced by Streptomyces roseosporus. It is a cyclic
molecule with a decanoyl fatty acid side chain attached to the exocyclic, N-terminal single tryp-
tophan residue [10]. It contains thirteen amino acid residues, some of which are non-standard
ones, including a kynurenine and an ornithine (Figure 2.1). Daptomycin possesses rapid bac-
tericidal activity against a broad spectrum of Gram-positive pathogens [133, 132]. It is active
against difficult pathogens such as vancomycin-resistant staphylococci and enterococci [83].
Daptomycin is approved for clinical use in the treatment of Staphylococcus aureus, includ-
ing MRSA, in bacteremia, right-sided endocarditis, and complicated skin and skin structure
infections.
Most of the results presented in this chapter have been published in: “Oligomerization of daptomycin
on membranes”, by Muraih, J.K., Pearson, A., Silverman, J. and Palmer, M. (2011), Biochim Biophys Acta
1808:1154-60.
Authors’ contributions: The preparation of Alexa Fluor 350-daptomycin, as described in Section 2.2.2, and the



































































Figure 2.1 Structures of fluorescently labeled daptomycin derivatives used in this study (NBD-
daptomycin and Alexa Fluor 350-daptomycin). The decanoyl residue is attached to the exocyclic
N-terminal tryptophan residue. The ornithine residue carries the sole free amino group, which is
free in daptomycin but labeled with the fluorophores NBD or Alexa Fluor 350 in the two derivatives.
The kynurenine residue possesses intrinsic fluorescence.
The bactericidal activity of daptomycin is mediated by membrane permeabilization and
depolarization [125]. It is calcium-dependent and applies to both resting and proliferating
cells [92]. Susceptibility of bacteria to daptomycin is correlated with the membrane content
of phosphatidylglycerol; it is decreased by mutations that promote the conversion of phos-
phatidylglycerol to lysylphosphatidylglycerol [47]. On bacterial cell membranes, fluorescently
labeled daptomycin localizes to phosphatidylglycerol-rich membrane areas [52].
Membrane-permeabilizing proteins and peptides commonly form oligomeric structures on
the target membrane. Daptomycin oligomers have been detected in solution at relatively high
(0.75 mM) concentrations, and the formation of oligomers prior to membrane binding has
been interpreted as an integral step in daptomycin activity [9]. However, there is as yet no
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experimental evidence of daptomycin oligomers on the lipid membranes.
In the present study, we have examined the oligomerization of daptomycin both in solution
and on membranes. To this end, we used daptomycin derivatives fluorescently labeled with
NBD (7-nitro-2,1,3-benzoxadiazol) and with Alexa Fluor 350. Oligomerization was detected
through fluorescence resonance energy transfer (FRET) as well as through the self-quenching
of NBD fluorescence. We detected oligomerization on liposome membranes containing phos-
phatidylglycerol, combined with either phosphatidylcholine (PC) or phosphatidylethanolamine
(PE) plus cardiolipin (CL), as well as on membrane vesicles prepared from Bacillus subtilis
(ATCC 6633) cells. In contrast, no oligomerization was observed with liposomes containing
phosphatidylcholine alone, nor in solution at daptomycin concentrations similar to those re-
quired for antibacterial activity. The requirements that we find for oligomerization correlate
with those for membrane permeabilization and bacterial susceptibility [10, 47], suggesting that
the membrane lesion is caused by the daptomycin oligomer.
2.2 MATERIALS AND METHODS
2.2.1 Preparation of NBD-daptomycin
Unlabeled daptomycin was supplied by Cubist Pharmaceuticals Inc. (Lexington, MA, USA).
NBD-Cl (4-Chloro,7-nitro-2,1,3-benzoxadiazol, or 7-chloro-4-nitrobenzofurazan) was bought
from Fluka (Fluka, St. Louis, MO, USA). All other chemicals were obtained from Bioshop
(Burlington, ON) and were of analytical grade. Daptomycin (0.6 mM) was dissolved in 50
mM sodium borate buffer (pH 8) containing 20 mM EDTA. NBD-Cl (25 mM) was dissolved
in acetonitrile. 300 µl of daptomycin solution and 100 µl of NDB-Cl solution were mixed in a
reaction vial and incubated at 60 °C for 2h. The mixture was then cooled in an ice water bath
for 2 minutes, and finally acidified by adding 400 µl of acetic acid (50 mM) to stop the labeling
reaction.
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An HPLC system (Waters 625 LC) was used to purify the labeled daptomycin on a reversed-
phase column (Agilent, Eclipse XDB-C8, 150 x 4.6 mm). The mobile phase was 20 mM am-
monium acetate (pH 5.5) with an acetonitrile gradient from 30 to 40% and a flow rate of 1 ml/min
[90, 134]. Fractions were examined by spectrophotometry, spectrofluorometry (see below),
and mass spectrometry using a Micromass Q-TOF Ultima GLOBAL mass spectrometer. The
molecular weight of the purified NBD-labeled daptomycin determined by mass-spectrometry
was 1783.7 Da. This corresponds to the expected molecular weight of 1784 Da for the stoi-
chiometric adduct (Figure 2.1). To determine the concentration, we assumed a molar extinction
coefficient at 476 nm of 24,000 as previously determined for the NBD-adduct of alanine [79].
2.2.2 Preparation of Alexa Fluor 350-daptomycin
Daptomycin trifluoroacetate salt (20.34 mg, 0.013 mmol) was dissolved in DMF at 0 °C. Alexa
Fluor-350 succinimide (Molecular Probes, 5 mg, 0.013 mmol) was added and stirred for 5 min.
Hünig’s base (N,N-diisopropylethylamine) was added and the reaction mixture was stirred
for 60 min. The reaction solution was poured into a flask containing cold diethylether (35
mL), which led to precipitation. The precipitate was collected by centrifugation, washed with
diethylether and again recovered by centrifugation. The material was dried under high vacuum
and then purified via HPLC.
2.2.3 Preparation of large unilamellar vesicles (LUV) and of bacterial membrane
vesicles
All phospholipid compounds—1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-di-
myristoyl-sn-glycero-3-[phospho-(1-glycerol)] (DMPG), 1-palmitoyl-2-oleoyl-sn-glycerol-3-
phosphoethanol (POPE), 1,2-dioleoyl-sn-glycerol-3-phospho-(1-rac-glycerol) (DOPG), and
1,3-bis[1,2-dioleoyl-sn-glycero-3-phospho]-sn-glycerol (cardiolipin; TOCL)—were obtained
from Avanti Polar Lipids, Inc. (Alabaster, AL, USA).
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The required amounts of DMPC and DMPG, or of POPE, DOPG and cardiolipin, were
weighed, dissolved in chloroform and transferred to a round-bottom flask. The solvent was
evaporated with nitrogen and the resulting lipid films further dried under vacuum for three
hours. The lipids were then suspended in HEPES buffer (20 mM, pH 7.4) containing 150 mM
sodium chloride. Finally, the suspension was extruded 10-15 times through 100 nm polycar-
bonate filters, using a nitrogen-pressurized extrusion device [94]. The liposomes were em-
ployed in the fluorescence experiments at a final concentration of 250 µM of lipid.
Bacterial membranes were prepared from Bacillus subtilis, grown in LB broth, according
to the procedure described by Konings et al. [72], except that the Potter homogenization was
omitted, and the membranes were treated with a probe sonicator on ice for 2 minutes instead.
Again as in the same reference [72], the membrane vesicles obtained were quantitated by as-
saying for membrane protein using the Lowry method.
2.2.4 Antibacterial activity tests for daptomycin and NBD-daptomycin
2.2.4.1 Disc diffusion. A disk diffusion test was used primarily to determine antibacterial
activity of unlabeled daptomycin and its derivative NBD-daptomycin. Petri dishes containing
LB-Agar, supplemented with calcium (5 mM), were streaked with a liquid culture of Bacillus
subtilis. Paper disks were cut from Whatman grade 1 filter paper with a hole punch, soaked
in daptomycin or NBD-daptomycin dissolved at various concentrations, blotted dry on a sheet
of filter paper, and placed on top of the inoculated agar plates. The plates were incubated
overnight at 37 °C, and the zones of inhibition measured with a ruler.
2.2.4.2 Broth dilution. A broth dilution is more accurate than the disc diffusion. NBD-
daptomycin and unlabeled daptomycin were tested for antibacterial activity by broth dilution.
LB broth was supplemented with calcium (5 mM) and daptomycin and NBD-daptomycin, re-
spectively, at concentrations of 10, 5, 3, 2, 1.5, and 1 µg/ml. Growth controls without antibiotic
were also included. Each tube was inoculated with Bacillus subtilis ATCC 6633 and incubated
overnight at 37 °C. Growth inhibition was evaluated visually by turbidity.
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2.2.5 Fluorescence studies
Emission spectra and time-based scans were acquired on a QuantaMaster 4 spectrofluorimeter
(Photon Technology International, London, ON). Kynurenine fluorescence was excited at 365
nm and the emission recorded from 400 to 600 nm. NBD fluorescence was excited at 465 nm
and the emission recorded from 490 to 600 nm. Alexa Fluor 350 was excited at 350 nm and
emission recorded from 400 to 600 nm. Bandpasses for excitation and emission were between
2 and 5 nm. The steady state spectra shown were acquired at 37 °C; spectra acquired at room
temperature were virtually indistinguishable.
The concentrations of calcium, where present, were 200 mM with PC liposomes and 5 mM
in all other cases. For the calculation of the Förster radius [43] for kynurenine and NBD on
PC/PG membranes, the quantum yield of kynurenine (0.039) was obtained by comparison to
a quinine sulfate standard. The spectral overlap integral for donor emission and acceptor ab-
sorbance was determined from the absorption spectrum of NBD-daptomycin (see Figure 2.2)
and the emission spectrum of unlabeled daptomycin on DMPC/DMPG membranes in the pres-
ence of calcium, with correction for the wavelength-dependent sensitivity of the spectrofluo-
rimeter. For the orientation factor κ2, a value of 2/3 was used, which applies in the commonly
assumed case of randomly distributed orientations of donor and acceptor [43].
Fluorescence lifetime measurements were performed on a FluoTime 100 Lifetime spec-
trometer using a P-C-370 diode laser light source (PicoQuant, Berlin, Germany). The lifetime
instrument did not have a thermostatted cell holder, and therefore lifetime measurements were
performed at room temperature. Kynurenine emission was isolated using a 460±10 nm band
pass filter (Melles-Griot, Brossard, QC). Experimental decays were numerically fit with three
exponentials, with resulting x2 values typically below 1.2. From these three components, aver-
age lifetimes were calculated according to the equation:
< τ >= ∑αiτi
∑αi
(2.1)
where αi represents the amplitude at time zero and τi the lifetime of the ith component.
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2.2.6 Numerical fitting
Numerical fits were performed with Gnuplot. The effect of Ca++ on the fluorescence of dap-
tomycin and NBD-daptomycin on membranes (Figure 2.4) was fit with the Hill equation, as
follows:




with K and n as variable parameters. The kinetics of the decrease of daptomycin fluorescence
in the presence of EDTA (Figure 2.8) was fit with a triple-exponential model, as follows:







with baseline and all pre-exponentials (a, b, c) and lifetimes (τa, τb, τc) as variable parameters.
2.3 RESULTS
2.3.1 Characterization of NBD-daptomycin
The absorption and emission spectra of purified NBD-daptomycin are shown in Figure 2.2C.
The main absorbance peak of NBD-daptomycin occupies a very similar spectral position as
the kynurenine fluorescence emission peak of unlabeled daptomycin (Figure 2.2A). This spec-
tral overlap indicates that fluorescence energy transfer (FRET) will occur from kynurenine to
NBD. Indeed, when the kynurenine residue in NBD-daptomycin is excited (at 365 nm), the
only fluorescence peak observed is that typical of NBD, indicating that virtually all photons
absorbed by kynurenine are transferred to NBD through FRET.
The antibacterial activity against Bacillus subtilis of NBD-daptomycin was identical to that
of unmodified daptomycin (MIC = 3 µg/ml). Alexa Fluor 350-daptomycin was found to be 8-16
fold less active than unlabeled daptomycin in standard broth dilution assays. In a disk diffusion
test for activity also against Bacillus subtilis, NBD-daptomycin at 81 µg/ml produced a zone of











































































































Figure 2.2 Absorbance (dashed lines) and fluorescence emission (solid lines) spectra of (A) dap-
tomycin, (B) Alexa Fluor 350-daptomycin and (C) NBD-daptomycin. The kynurenine residue in
daptomycin causes the absorbance peak around 360 nm and the emission peak at 460 nm. The
absorbance and emission peaks of Alexa Fluor 350-daptomycin occur in similar positions. NBD-
daptomycin has an absorbance peak at 475 nm that overlaps the emission peaks of the other two;
this overlap causes fluorescence resonance energy transfer (FRET) from daptomycin and Alexa
Fluor 350-daptomycin to NBD-daptomycin. Direct excitation at 475 nm allows the observation of
NBD fluorescence alone.
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The results indicate that NBD-daptomycin retains antibacterial activity very similar to that
of unmodified daptomycin, and therefore that it should be a valid model to study the interaction
of daptomycin with membranes.
2.3.2 Calcium-dependent membrane interaction of daptomycin and NBD-daptomycin
It has previously been reported that the kynurenine fluorescence of daptomycin increases in in-
tensity and undergoes a blue shift upon interaction with calcium and negatively charged phos-
pholipid membranes, composed of phosphatidylcholine and phosphatidylglycerol [77]. Such
changes are observed with many fluorophores upon transition from a more polar environment
to a less polar one, such as the hydrophobic interior of a lipid bilayer. A similar change in the
fluorescence signal also occurs on neutral (PC) membranes (Figure 2.3A). However, the gain
in intensity is less, and the position of the fluorescence peak is different from that observed on
PC/PG membranes, suggesting a different environment of the kynurenine residue and, hence,
a different conformation of the daptomycin molecule [68, 77]. Also note that with PC alone
the fluorescence change occurs only at a far higher concentration of calcium.
NBD-daptomycin also gains in fluorescence intensity in the presence of membranes and
calcium (Figure 2.3B). Here the fluorescence gain appears larger on PC membranes than on
PC/PG membranes, although the opposite is actually true after NBD self-quenching on PC/PG
membranes is accounted for (compare Figure 2.6, below). The spectral difference indicates
that the labeled residue (ornithine), like the kynurenine residue, senses different environments
on the two types of membranes.
Figure 2.4 shows the response of the kynurenine fluorescence of daptomycin and of the
NBD fluorescence of NBD-daptomycin, respectively, to increasing Ca2+ concentrations, on
DMPC/DMPG membranes and DMPC membranes. On both membranes, the NBD fluores-
cence and the kynurenine fluorescence respond at similar calcium concentrations, further sug-



































Figure 2.3 Fluorescence emission spectra of daptomycin (4.8 µM) (A), and of NBD-daptomycin
(0.91 µM) on liposome membranes (B), in the absence and presence of calcium. The liposomes
consisted of phosphatidylcholine and phosphatidylglycerol (DMPC/DMPG) or phosphatidylcholine
only (DMPC) at saturating calcium concentrations. The excitation wavelength was 365 nm with na-
tive daptomycin and 465 nm with NBD-daptomycin. The two samples without calcium are normal-
ized to the same maximum intensity and represented as dotted lines; the two samples containing
calcium on PC/PG (solid lines) and PC only (dashed lines) were scaled accordingly, so that the
relative gains in intensity upon addition of calcium and lipids can be compared.
2.3.3 Detection of daptomycin oligomerization on membranes by FRET
The efficiency of FRET is distance-dependent, and it can approach 100% if the distance be-
tween the donor and an acceptor is well below the Förster radius (R0). For kynurenine in unla-
beled daptomycin as the donor, bound to DMPC/DMPG membranes, and NBD-daptomycin as
the acceptor, we estimated R0 as 2.7 nm (see Methods section). Since the daptomycin molecule
is smaller than that, formation of hybrid oligomers from daptomycin and NBD-daptomycin
should cause FRET from the unlabeled to the labeled species. However, some degree of FRET
should also occur without oligomerization, due to the proximity of some donors and acceptors
when both are randomly distributed in the membrane plane [144].
To distinguish between these two effects, we measured FRET at different ratios of dap-
tomycin to NBD-daptomycin, while keeping the absolute concentration of NBD-daptomycin
constant. The rationale of this experiment is as follows: If donors (daptomycin) and acceptors
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Figure 2.4 Increase in fluorescence intensity of kynurenine of daptomycin (A) and of NBD of NBD-
daptomycin (B) in response to increasing calcium concentrations, incubated with DMPC/DMPG
membranes (filled circles) and with PC membranes (empty circles), respectively. The solid lines
are least squares fits to the Hill equation; the respective fitted values of the Hill coefficient (n) are
stated next to each curve.
(NBD-daptomycin) remain monomeric and separate, the efficiency of FRET, as measured by
the reduction of donor emission, varies only with the acceptor concentration but not the donor
concentration [144]; hence, the extent of FRET should not vary between the samples in our
experiment. On the other hand, if donor and acceptor form hybrid oligomers, the probability
for a donor to end up within close proximity to an acceptor molecule will increase with the rel-
ative amount of acceptors present. Therefore, at a fixed concentration of NBD-daptomycin, the
efficiency of FRET should increase with decreasing concentration of unlabeled daptomycin.
FRET can be observed both with time-resolved (Figure 2.5A) and with steady-state fluores-
cence measurements (Figure 2.5B). In the time-resolved experiment, an increase in FRET cor-
responds to a decrease in the donor’s excited state lifetime. Figure 2.5A shows that, on DMPC
membranes, the lifetime is almost the same at donor-acceptor ratios of 16:1 and 1:1, indicat-
ing no change in FRET and therefore no oligomerization. In contrast, on PC/PG membranes,
the same change in the donor to acceptor ratio causes a fourfold reduction in the kynurenine
lifetime, indicating that oligomerization occurs on these membranes.





















































Figure 2.5 FRET experiments on the oligomerization of daptomycin. A: Kynurenine fluorescence
lifetimes in mixtures of daptomycin and NBD-daptomycin, on PC/PG and PC membranes with
saturating concentrations of calcium. The concentration of NBD-daptomycin was 1.36 µM, where
present; the concentration of unlabeled daptomycin is implied by the indicated molar ratios. The two
unconnected data points were obtained with unlabeled daptomycin only. B: Fluorescence emission
spectra of daptomycin (4.8 µM), and of NBD-daptomycin (0.91 µM), either alone or together, on
DMPC/DMPG membranes. In the premixed sample, daptomycin and NBD-daptomycin were mixed
before addition of membranes and calcium. In the sequential sample, daptomycin and calcium were
added to the membranes and incubated for 30 minutes before application of NBD-daptomycin.
and PC/PG membranes, the kynurenine lifetime is significantly longer than with those samples
that contain the equivalent amount of donor but with NBD-daptomycin present. This difference
reflects FRET between molecules that are not part of the same oligomers, and thus is not an
indication of oligomerization.
In steady-state fluorescence spectra (Figure 2.5B), the kynurenine peak was much lower
with mixtures of daptomycin and NBD-daptomycin than with daptomycin only, indicating ex-
tensive FRET. This FRET should occur in part within oligomers and in part between oligomers.
When daptomycin and NBD-daptomycin were applied to PC/PG membranes sequentially, with
time allowed for the oligomerization of NBD-daptomycin before addition of the daptomycin,
the drop in donor intensity was reduced by half. The most likely interpretation is that in this
sample the labeled and the unlabeled molecules had formed separate oligomers, thus removing
the component of FRET that occurred within hybrid oligomers, and leaving only the compo-
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nent between separate oligomers. The spectra of such samples did not change substantially
over two hours, indicating that most oligomers remained intact over this length of time.
2.3.4 Detection of oligomerization by NBD self-quenching; oligomerization on
bacterial membranes
Like many other fluorophores, NBD undergoes self-quenching at high concentration, which
likely involves FRET from monomeric NBD molecules to non-fluorescent aggregated pairs
[21]. In oligomers that consist of NBD-daptomycin only, the local concentration of NBD
groups, and thus the likelihood of aggregation will be higher than in mixed oligomers with
unlabeled daptomycin. Therefore, the fluorescence signal of a certain given amount of NBD-
daptomycin—after direct excitation at 465 nm, eliminating any FRET from kynurenine—
should increase in the presence of unlabeled daptomycin. On the other hand, without oli-
gomerization, the extent of self-quenching should be unaffected by the presence of unlabeled
daptomycin, and therefore the NBD-fluorescence should remain unchanged. Therefore, self-
quenching of NBD-daptomycin should also be a viable method for detecting daptomycin oli-
gomerization.
These expectations are borne out by observations on PC/PG membranes and PC mem-
branes, respectively. Addition of unlabeled daptomycin relieves self-quenching of NBD-dap-
tomycin on PG/PC membranes (Figure 2.6A), while no such effect occurs with PC alone (Fig-
ure 2.6B). These observations confirm that oligomerization occurs only in the presence of PG.
The composition of Bacillus cereus and Bacillus subtilis cell membranes has been modeled
with liposomes consisting of cardiolipin (TOCL, 17%), phosphatidylglycerol (DOPG, 40%)
and phosphatidylethanolamine (POPE, 43%) [39, 86]. On such liposome membranes, relief
of NBD self-quenching by addition of unlabeled daptomycin is again observed (Figure 2.6C).
The same applies to membrane vesicles prepared from Bacillus subtilis bacterial cells (Fig-
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Figure 2.6 Fluorescence of NBD-daptomycin (0.91 µM) on (A) DMPC/DMPG liposomes, (B) PC
liposomes, (C) POPE/DOPG/TOCL liposomes and (D) Bacillus subtilis membrane vesicles, without
(solid lines) or with (dashed lines) a fourfold excess with unlabeled daptomycin. Since the excitation
wavelength (465 nm) was outside the absorbance spectrum of kynurenine, differences in intensity
are not due to FRET from kynurenine but to NBD self-quenching within oligomers.
2.3.5 Daptomycin does not form oligomers in solution at antimicrobially active concentra-
tions
It has been previously reported that daptomycin forms oligomers in solution in the presence of
calcium. This was observed by both NMR [9, 68] and ultracentrifugation [61].
In both of the previous studies [9, 68], the concentration of daptomycin was in the millimo-
lar range. Fluorescence allows the observation of oligomerization at much lower concentra-
tions, similar to those required for antimicrobial activity. Because kynurenine has a very low
fluorescence intensity in aqueous solution, we here used daptomycin labeled with Alexa Fluor
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Figure 2.7 Requirements for daptomycin membrane binding and oligomerization. A: Alexa Fluor
350-daptomycin (0.175 µM; A) was incubated with Ca2+ (3 mM), with or without NBD-daptomycin
(0.88 µM; N) and with or without PC/PG membranes (125 µM; M). The two labeled species read-
ily form mixed oligomers on PC/PG membranes, as evident from the suppression of Alexa Fluor
fluorescence through FRET. Without membranes, no FRET is observed, indicating absence of oli-
gomerization. B: Alexa Fluor 350-daptomycin (A) was incubated with PC membranes (M), with or
without NBD-daptomycin (N) and with or without Ca2+ (200 mM; all other concentrations as in panel
A). In the presence of both PC membranes and calcium, Alexa Fluor 350-daptomycin undergoes
an increase in fluorescence intensity, which is likely due in part to kynurenine. In contrast, with the
two labeled species, the emission at 450 nm is diminished through FRET. Since daptomycin does
not oligomerize on PC membranes, this FRET is due to membrane binding alone. The absence
of FRET in the sample with NBD-daptomycin but without calcium indicates absence of membrane
binding.
350, which has a high intensity in both polar and apolar environments. The spectral positions
of excitation and emission of Alexa Fluor 350 are such that this labeled derivative can again be
combined with NBD-daptomycin in FRET experiments [110].
Figure 2.7A shows the interaction of Alexa Fluor 350-daptomycin and NBD-daptomycin
in solution and on PC/PG membranes, in the presence of calcium. On the membranes, Alexa
fluorescence is strongly reduced by FRET to NBD, which is consistent with oligomerization.
In contrast, no FRET occurs when the membranes are missing. This indicates that no oligo-
merization is happening; calcium-mediated oligomerization in solution therefore is restricted
to much higher concentrations and not relevant to the antimicrobial effect of daptomycin. As
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an aside, it is evident that without NBD-daptomycin, the fluorescence of Alexa Fluor 350-
daptomycin on membranes is still somewhat lower than without membranes; this suggests that
Alexa Fluor 350 is also subject to some degree of self-quenching upon oligomerization.
Figure 2.7B shows the interaction of Alexa Fluor 350-daptomycin and NBD-daptomycin
on PC membranes, with and without calcium. With calcium, there is FRET, albeit less than on
PC/PG membranes. Since no oligomerization occurs on PC, this FRET is due to membrane
binding of both Alexa Fluor 350-daptomycin and NBD-daptomycin; membrane binding brings
them much closer to each other than they are in solution. No FRET occurs with PC but without
calcium, indicating that calcium is required for membrane binding.
2.3.6 Effect of EDTA on membrane-bound daptomycin oligomers
Calcium induces changes of daptomycin fluorescence and presumably of conformation on
both neutral and negatively charged membranes; judging by both fluorescence and ability to
oligomerize, these conformations are different. Calcium also commonly forms bridges be-
tween negative charges on proteins and phospholipid membranes; examples are annexins and
coagulation factors that bind to phosphatidylserine in a calcium-dependent manner. Taken to-
gether, these observations suggest that there may be different types of calcium binding sites in
the daptomycin/PC/PG system, some or all of which may involve PG. If so, the kinetic rates of
Ca2+ dissociating from these sites would likely be different, which in turn might be reflected in
the time course of fluorescence changes triggered by calcium depletion.
Figure 2.8 shows the time course of the kynurenine fluorescence of daptomycin on PC/PG
membranes, following the addition of EDTA at time zero. The decrease in fluorescence is evi-
dently not single-exponential. It can be fit with three exponential components, which comprise
two short lifetimes (48 and 140 seconds, respectively) and one that is much longer (3351 sec-
onds). This suggests the existence of at least two different classes of calcium binding sites.
On PC membranes, the fluorescence dropped to a low, stable level within a few seconds of
EDTA addition (data not shown). Together, these results suggest that the negative charge of
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Figure 2.8 Time course of kynurenine fluorescence of daptomycin incubated with 6 mM Ca2+ and
PC/PG membranes, after addition of 10 mM EDTA at 0 seconds. The dotted line superimposed to
the experimental data points is the sum of three fitted exponential components that are represented
by straight dashed lines. The time constants of these components are 48, 140 and 3351 seconds,
respectively. A baseline of 240,000 cps that also resulted from the fit was subtracted from the
experimental curve before plotting.
PG is involved in the slowly dissociating calcium binding sites, and possibly also the faster
dissociating ones observed on PC/PG membranes.
If the distinction between fast-dissociating and slow-dissociating Ca2+ binding sites is
valid, it is conceivable that one but not the other is necessary for oligomerization. When
EDTA was added to a sample of daptomycin and NBD-daptomycin, sequentially incubated
with PC/PG membranes as in (Figure 2.5B), and Ca2+ was then replenished after 180 seconds,
the kynurenine fluorescence rebounded but to a much reduced level, whereas the NBD fluo-
rescence was increased. This suggests that withdrawal of Ca2+ from the fast-dissociating sites
suffices to disrupt the initially segregated daptomycin and NBD-daptomycin oligomers; the re-
leased monomers then mingle and reassemble into hybrid ones that show an increased level of





While it has been proposed previously that daptomycin forms oligomers on membranes, this
study provides the first such experimental evidence. Oligomerization on membranes correlates
with the presence of phosphatidylglycerol, which coincides with the involvement of phos-
phatidylglycerol in bacterial susceptibility to daptomycin [47] and suggests that the daptomy-
cin oligomer is the functional membrane lesion.
Our findings can be summarized in the model of daptomycin activity shown in Figure 2.9.
In this model, binding of calcium to daptomycin causes a conformational change that in turn
triggers membrane binding, or, at sufficiently high concentration, oligomerization in solution
[68]. Membrane-bound daptomycin then interacts with phosphatidylglycerol, resulting in a
second conformational transition that leads to the formation of the oligomer. We propose
that the oligomer forms the functional membrane lesion, possibly enclosing a central aper-
ture as is the case with many pore-forming proteins and peptides, although differences in the
rate of daptomycin-induced membrane depolarization [125] and the absence of non-specific
membrane permeabilization [27] suggest that a classic pore may not be formed. Daptomycin
oligomerization was inferred here for PC/PG membranes from FRET experiments. This is fur-
ther corroborated by the highly cooperative change of kynurenine fluorescence as a function
of Ca+2 concentration on PC/PG membranes, which is characterized by a Hill coefficient of
2.7 (Figure 2.4). Conversely, the Hill coefficient of 1 on PC membranes again corroborates the
lack of oligomerization on these membranes.
The key aspects of this model, in particular the roles of calcium in membrane binding and
of phosphatidylglycerol in oligomerization, are supported by evidence; however, several de-
tails remain hypothetical. The postulated changes in conformation are inferred from those in
function. The initial change triggered by calcium binding may lead to an increased exposure
of hydrophobic moieties, possibly the N-terminal acyl chain; such a change would promote
both oligomerization in solution and binding to membranes. The second change, triggered by
phosphatidylglycerol, is depicted as causing not only oligomerization but also deeper mem-
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brane penetration. Both kynurenine [77] and NBD in NBD-daptomycin show a greater gain
of fluorescence intensity on PC/PG membranes than on PC membranes, indicating a more hy-
drophobic environment on the former. However, on PC/PG membranes, daptomycin will not
only interact with surrounding lipid molecules but also other daptomycin molecules within the
oligomer that forms only on these membranes. It should also be noted that PC/PG membranes
may be subject to lateral phase segregation, which is further promoted by calcium ions. If
this occurs, membranes may become leaky, which may expose additional sites for hydropho-
bic interaction. For these reasons, the increase in environmental hydrophobicity cannot be
unequivocally ascribed to deeper membrane penetration.
In Figure 2.9, the interaction of daptomycin with phosphatidylglycerol is assumed to be
mediated by calcium. Daptomycin has only one intrinsic positive charge, which is the amino
group in the side chain of the ornithine residue. With NBD-daptomycin, as well as with previ-
ously characterized ornithine-modified derivatives [59, 123], even this single charge is masked
(see Figure 2.1); nevertheless, these derivatives retain antimicrobial activity, which leaves cal-
cium as the only available positive charge available to interact with the negative charge of
phosphatidylglycerol. Not many more conclusions can be drawn as to the structure of the oli-
gomer, other than that it is fairly stable on a time scale of minutes to hours, as indicated by
the experiment shown in Figure 2.5. The structure of the membrane-associated oligomer thus
remains to be determined.
Regarding the experimental strategies used in this study, it should be noted that FRET
between daptomycin (or Alexa Fluor 350-daptomycin) and NBD-daptomycin can be quite ex-
tensive even in the absence of oligomerization, as is evident from Figures 2.5 and 2.7. The
extent of FRET will also vary with the ratio of total daptomycin to membrane lipids, and it will
also be affected by uneven distribution of membrane-bound daptomycin, as has been demon-
strated by fluorescence with bacterial cells [52]. In contrast, the relief of self-quenching of
NBD-daptomycin, caused by the addition of unlabeled daptomycin, is much less sensitive to















Figure 2.9 Model of daptomycin oligomerization on membranes. Calcium binds to daptomycin in
solution and causes a conformational change, which at high concentration facilitates oligomeriza-
tion in solution. It also facilitates binding to PC membranes, on which however no oligomerization
occurs. On PC/PG membranes, as well as on bacterial membranes, the interaction of dapto-
mycin/calcium with the negatively charged head-group of phosphatidylglycerol induces a second
conformational change that induces oligomerization and deeper membrane insertion.
merization, the addition of unlabeled daptomycin should cause no change in quenching, since
the unlabeled daptomycin would simply not interfere with the NBD-daptomycin in any way. In
contrast, with oligomerization, the addition of unlabeled daptomycin must reduce quenching,
since within the hybrid oligomers the NBD-daptomycin molecules will be less likely to closely
interact with one another. Therefore, the more robust quenching assay was preferred to detect
oligomerization on bacterial cell membranes.
In summary, we have shown that daptomycin oligomerizes on liposomal and bacterial
membranes. The requirements for oligomerization resemble those established for bacterial cell
membrane permeabilization, suggesting that the oligomer is the functional membrane lesion.
The detailed structure of the oligomer remains to be established.
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Chapter 3
Characterization of daptomycin oligomerization with excimer
fluorescence
3.1 INTRODUCTION
Daptomycin is a cyclic lipopeptide that consists of 13 amino acid residues, including one
kynurenine residue and several other non-standard amino acids, and a decanoyl fatty acyl
residue attached to the exocyclic N-terminal tryptophan residue (see Figure 3.1). It is pro-
duced by the soil bacterium Streptomyces roseosporus. Daptomycin is used in the treatment of
infections by Gram-positive bacteria such as enterococci and staphylococci, including strains
that are resistant to penicillin, methicillin and vancomycin [133, 132]. Daptomycin binds and
depolarizes the bacterial cytoplasmic membrane [125]. Its activity requires calcium and corre-
lates with the target membrane’s content of phosphatidylglycerol (PG); increased conversion
of PG to lysyl-PG confers partial resistance to bacterial cells [52, 53].
The results presented in this chapter have been published in: “Characterization of daptomycin oligomerization
with perylene excimer fluorescence: stoichiometric binding of phosphatidylglycerol triggers oligomer formation”,
by Muraih, J.K., Harris, J., Taylor, S.D., Palmer, M. (2012), Biochim Biophys Acta 1818:673-8.
Authors’ contributions: The preparation of pyrene- and perylene-daptomycin, as described in Sections 3.2.1



















































R= pyrene-butanoate perylene-butanoate decanoate daptomycin
Figure 3.1 Structures of daptomycin, and of the substituents pyrene- and perylene-butanoic acid
that were substituted for the decanoyl residue of the native compound in this study.
Using FRET between the kynurenine residue of unlabeled daptomycin and a fluorescently
labeled derivative of daptomycin, we have shown previously that daptomycin forms oligomers
on liposome membranes (see Chapter 2). Oligomerization occurs under conditions that resem-
ble those required for its antibacterial activity, suggesting that the oligomer is involved in the
bactericidal effect.
In this study, we have used excimer fluorescence in order to further characterize the mem-
brane-associated daptomycin oligomer. An excimer, or excited dimer, is a complex that forms
from one fluorophore molecule that is in the excited state and another one in the ground state
[78]. Since this requires direct contact between two fluorophore molecules, the detection of ex-
cimer fluorescence imposes a more stringent constraint on the distance of the interaction than
that implied by the observation of FRET.
The fluorophore most widely used to study excimer fluorescence is pyrene, whose excimer
and monomer spectra are well separated. However, as will be shown below, pyrene incorpora-
tion into daptomycin results in FRET from pyrene to kynurenine, which prevents the observa-
tion of excimer fluorescence. To circumvent this difficulty, we therefore chose to incorporate
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perylene, which emits at longer wavelengths [66] and therefore should not engage in FRET to
kynurenine.
A prior study has shown that substitutions of the N-terminal decanoyl moiety of daptomycin
are quite compatible with its antibacterial activity, as long as the introduced substituents retain
an overall hydrophobic character [33]. Pyrene and perylene are very hydrophobic molecules,
and accordingly they were introduced into daptomycin by replacing the decanoyl chain with
pyrene-butanoic acid and perylene-butanoic acid, respectively. The derivatives retained an-
tibacterial activity, albeit at a slightly reduced level in the case of perylene-daptomycin. Never-
theless, oligomer formation of perylene-daptomycin was clearly evident through excimer flu-
orescence, under conditions that mirrored those used in the previous FRET experiments. This
result indicates that the fatty acyl residues of adjacent subunits of the membrane-associated
daptomycin oligomer are within immediate reach of one another.
In a lipid bicelle system, the excimer fluorescence could be titrated with phosphatidylglyc-
erol. Conversion of monomer fluorescence to excimer fluorescence approached saturation at
an equimolar ratio of phosphatidylglycerol to daptomycin. Therefore, a single molecule of
phosphatidylglycerol is sufficient to convert daptomycin to a conformation that is competent
for oligomerization.
Our study provides significant additional insight into the process of daptomycin oligomer-
ization. At the same time, it demonstrates that perylene excimer fluorescence is useful as a
probe in the experimental study of biochemical systems.
3.2 METHODS AND MATERIALS
3.2.1 Synthesis of perylene-daptomycin
To a suspension of deacylated daptomycin bearing a Boc protecting group on the ornithine
residue (120 mg, 0.077 mmol; generously provided by Jared Silverman of Cubist Inc.) in
dry dimethylformamide (0.5 mL) was added 4-(3-perylenyl)butanoic acid succinimidyl ester
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(0.035 g, 0.08 mmol). The mixture was stirred for 24 h and then concentrated by high vac-
uum rotary evaporation. The residue was dissolved in water and lyophilized. The lyophilized
powder was dissolved in an ice-cold solution of trifluoroacetic acid (TFA) containing 2%
thioanisole, and the resulting solution was stirred for 15 min at 0 °C (ice bath). The mix-
ture was concentrated using a high vacuum rotary evaporator, keeping the heating bath below
40 °C. The residue was dissolved in water and lyophilized. The resulting crude powder was
purified by semi-preparative reversed-phase HPLC employing a linear gradient starting with
95% water (0.1% TFA) to 5% acetonitrile to 100% acetonitrile over 50 minutes (tr = 34 min).
Fractions containing the desired product were pooled and concentrated using a high vacuum
rotary evaporator keeping the heating bath below 40 °C. The resulting residue was lyophilized
to give 0.047 g (34% yield) of perylene-daptomycin as a yellow powder. The molecular weight
of the purified perylene-daptomycin determined by mass spectrometry was 1784.76 Da.
The analytical reversed-phase HPLC chromatogram of the purified material, using a linear
gradient starting with 95% water (0.1% TFA) and 5% acetonitrile to 100% acetonitrile over 50
min. Relevant figures and more details are provided in the supporting data for reference [100].
3.2.2 Synthesis of pyrene-daptomycin
This compound was prepared using essentially the same procedure as that described above for
perylene-daptomycin, substituting 0.0081 g (0.021 mmol) 1-pyrenebutanoic acid succinimidyl
ester for the analogous perylene compound. The amount of Boc-protected deacylated dapto-
mycin used was 0.030 g (0.019 mmol). The crude reaction product was purified by HPLC as
described above for perylene-daptomycin (tr = 28 min). Fractions containing the desired prod-
uct were pooled and concentrated and the resulting residue lyophilized to give 17 mg (51%
yield) of pyrene-daptomycin as a white powder. The molecular weight of the purified pyrene-
daptomycin determined by mass spectrometry was 1734.75 Da. Analytical data are contained
in the supporting data for reference [100].
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3.2.3 Antibacterial activity test for pyrene- and perylene-daptomycin
The two labeled derivatives as well as native daptomycin were tested for antibacterial activ-
ity by broth dilution. LB broth was supplemented with calcium (5 mM), and the daptomycin
derivative in question was added at concentrations of 10, 5, 3, 2, 1.5, and 1 µg/ml. Each tube
was inoculated with Bacillus subtilis ATCC 1046 and incubated overnight at 37 °C. Growth in-
hibition was evaluated visually by turbidity. Growth controls without antibiotic were prepared
for comparison.
3.2.4 Lipids and liposomes
The preparation of large unilamellar vesicles (LUV) was performed as described above in
Section 2.2.3. Dihexanoyl-PC (DHPC) was obtained from Avanti Polar Lipids Inc. (Alabaster,
AL) and used directly.
3.2.5 Fluorescence measurements
Emission spectra were acquired on a QuantaMaster 4 spectrofluorimeter (Photon Technology
International, London, ON). Pyrene fluorescence was excited at 340 nm and the emission
recorded from 360 to 600 nm. Perylene fluorescence was excited at 430 nm and the emission
recorded from 440 to 600 nm. Bandpasses for excitation and emission were between 2 and 5
nm, depending on the sample concentration. Emission spectra were corrected for wavelength-
dependent instrument response using a quinine sulfate standard and a tabulated normalized qui-
nine spectrum listed in reference [78]. Fluorescence lifetime measurements were performed on
a FluoTime 100 Lifetime spectrometer (PicoQuant, Berlin, Germany), using diode laser light
sources emitting at 370 nm and at 440 nm for pyrene and perylene, respectively. The emission
was isolated using 460±10 nm or 560±10 nm bandpass filters (Melles-Griot, Brossard, QC).
Experimental decays were numerically fitted with two or three exponentials, with resulting
x2 values typically between 1.1 and 1.3. From these fitted exponential components, average
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lifetimes were calculated according to the equation





were αi represents the amplitude at time zero and τi the lifetime of the ith component.
All measurements were acquired at room temperature. The concentration of calcium was
200 mM with liposomes consisting of PC only. With all other samples, the calcium concentra-
tion was 5 mM, unless stated otherwise.
3.2.6 Deconvolution of perylene excimer and monomer spectra
Perylene fluorescence decays were measured at 560±10 nm on DMPC/DMPG membranes,
both with pure perylene-daptomycin and with a mixture of perylene-daptomycin and a fivefold
excess of unlabeled daptomycin. The decays were fitted to a two-exponential model. The
fractional emission intensities of the monomer and the excimer at 560 nm were obtained from
these data according to




Fexcimer,560 = 1−Fmonomer,560 (3.3)
From the spectrum of perylene-daptomycin only, P, and the spectrum of the mixture of pery-
lene-daptomycin with unlabeled daptomycin, U, the pure excimer spectrum, E, was calculated
as
E = P−aU (3.4)
with
a =
F P, monomer, 560 I P, 560
F U, monomer, 560 I U, 560
(3.5)
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where I P, 560 and I U, 560 denote the intensity of P and U at 560 nm, respectively. The pure
monomer spectrum M was obtained analogously. After normalizing E and M to the same
quantity of molecules, the quantum yield of the excimer, relative to that of the monomer, was
calculated from the ratio of the areas of the two normalized spectra.
3.2.7 Titration of perylene excimer fluorescence with phosphatidylglycerol
To a solution of 100 µM perylene-daptomycin, 1 mM Ca2+ and 20 mM DHPC in HEPES
buffer (HBS), a mixture of DMPC and DMPG (molar ratio, 4:1) was added in a stepwise
fashion. After each addition, the mixture was incubated for 2 min before acquisition of the
perylene emission spectrum. Repeated scans showed that this short incubation sufficed to
reach equilibrium. From each spectrum, the ratio of the emission intensities at 521 nm and 480
nm was calculated, and the increment was plotted as a function of the molar ratio of DMPG to
perylene-daptomycin.
3.3 RESULTS
3.3.1 Antibacterial activity of pyrene- and perylene-daptomycin
The antibacterial activities of pyrene-daptomycin and perylene-daptomycin (structures shown
in Figure 3.1) against B. subtilis strain ATCC 1046 were determined by broth dilution, using na-
tive daptomycin as a reference. The minimum inhibitory concentration of perylene-daptomycin
was 3 µg/ml, compared to 1 µg/ml for native daptomycin and pyrene-daptomycin. Therefore, the
specific activity of perylene-daptomycin is approximately 3 times lower than that of native
daptomycin and of pyrene-daptomycin.
3.3.2 Fluorescence of pyrene-daptomycin
Figure 3.2 shows the emission spectra of pyrene-daptomycin in solution and on liposomes



























Figure 3.2 Fluorescence emission spectra of pyrene-daptomycin in solution and on DMPC/DMPG
liposomes, in the presence of 6 mM calcium. The excitation wavelength was 340 nm.
orescence, which is apparent in the small peaks to both sides of 380 nm, is very low in both
samples. There is a broad peak around 460 nm that greatly increases after incubation with
the liposomes, on which daptomycin has been shown to form oligomers. While oligomer for-
mation should be accompanied by excimer formation, the latter should be accompanied by a
decrease of monomer emission; however, monomer emission is very low to begin with and
does not decrease any further. Furthermore, the peak at 460 nm has an average excited state
lifetime of approximately 3.4 ns as shown in Table 3.1, whereas the typical lifetimes of pyrene
excimers are much longer. On the other hand, the observed lifetime is very similar to that found
previously for the kynurenine residue of daptomycin [102].
The monomer emission spectrum of pyrene significantly overlaps the absorption spectrum
of the kynurenine residue,which should cause fluorescence energy transfer from excited pyrene
to kynurenine. The increase in the sensitized kynurenine emission upon membrane binding
mirrors that of directly excited kynurenine fluorescence reported earlier [77]. In sum, because
of spectral overlap between pyrene emission and kynurenine absorption, pyrene-daptomycin
does not produce experimentally useful excimer fluorescence.
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Table 3.1 Fluorescence lifetimes of pyrene-daptomycin and native daptomycin on DMPC/DMPG
and DMPC liposome membranes. Both pyrene and kynurenine fluorescence decays were mea-
sured by using diode laser light source at 370 nm. Fluorescence emission was isolated using a
460 ± 10 nm bandpass filter. The decays were fitted to a two-exponential model, and average
lifetimes were calculated according to equation 3.1.
PC/PG PC
Native daptomycin 2.941 ns 1.645 ns
Pyrene-daptomycin 3.387 ns 2.049 ns
3.3.3 Observation of perylene-daptomycin excimer fluorescence
The emission spectrum of perylene-daptomycin in solution resembles that of monomeric, free
perylene in hexane [66], with three distinct peaks between 450 and 520 nm (Figure 3.3A). A
similar spectrum is obtained when perylene-daptomycin is incubated with DMPC membranes
(Figure 3.3B). In contrast, on membranes composed of DMPC and DMPG, as well as on bac-
terial cells, the shape of the spectrum changes significantly (Figure 3.3C, D). The two leftmost
peaks are greatly decreased, and a new, broad peak emerges that overlaps the monomer fluo-
rescence.
While the new peak is centered around 525 nm and therefore is blue-shifted relative to the
excimer of free perylene [66], its shape nevertheless is suggestive of excimer fluorescence.
This interpretation is corroborated by time-resolved fluorescence measurements. Figure 3.4
shows fluorescence decays of perylene-daptomycin on PC liposomes (A) and on PC/PG lipo-
somes (B), measured at 560 nm, where monomer intensity is very low. Both decays can be
fitted quite well with a two-exponential model (see fit parameter values in the figure), and the
lifetime parameters obtained from these fits are similar to those of perylene monomers and
excimers reported earlier [66]. Note that the pre-exponentials are different between the two
membranes, which reflects a higher prevalence of excimers on the PC/PG membranes. Also,












































































































bacterial cells, Ca2+ 6 mM
Figure 3.3 Fluorescence emission spectra of perylene-daptomycin in solution (A), on DMPC li-
posomes (B), on DMPC/DMPG liposomes (C), and on bacterial cells (D). The emission spectra
were measured with 2.5 µM perylene-daptomycin. In (A), the absorption spectra (OD) of perylene-
daptomycin (PD) and of native daptomycin (ND) at 50 µM in solution are also shown. The absorp-
tion spectrum of native daptomycin on membranes is indistinguishable (not shown). In (D), the cells
were incubated with perylene-daptomycin and calcium, then washed repeatedly by centrifugation
to remove unbound daptomycin and resuspended before acquisition of the spectrum.
Excimer fluorescence only occurs when a monomer in the excited state binds directly to a
another monomer that is in the ground state. It should therefore be greatly facilitated by the
formation of stable oligomers, since within these the perylene moieties should remain close to
one another throughout. On the other hand, a mixture of perylene-daptomycin with an excess
of unlabeled daptomycin should produce hybrid oligomers, within which the perylene-labeled
molecules should become separated from one another by intervening unlabeled molecules.
This should lead to an increase in monomer fluorescence and a decrease in excimer fluores-
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Figure 3.4 Time-resolved fluorescence measurements of perylene-daptomycin on DMPC (A) and
DMPC/DMPG (B) membranes. Sample composition was as in Fig. 3B and C, respectively. Excita-
tion was with a 440 nm diode laser. Emission was measured using a 560±10 nm bandpass filter.
The decays were fitted to a two-exponential model. Pre-exponentials (α) and lifetimes (τ) of the
fitted components, as well as the residuals and χ2 of the fits are given.
cence. Figure 3.5 shows that this is indeed the case. It also shows that, on PC membranes,
the ratio of excimer fluorescence to monomer fluorescence is not affected by the addition of
unlabeled daptomycin. This is in line with the assumption that stable oligomers do not form
on these membranes, and that excimer fluorescence arises by diffusional collision of individual
perylene-daptomycin molecules only.
Large unilamellar vesicles consisting of POPE, DOPG and TOCL are considered models
of the cytoplasmic membranes of bacteria [39, 86]. With such liposomes, the spectra and
fluorescence lifetimes closely resembled those observed with PC/PG liposomes. These results
agree with previous observations using FRET between daptomycin molecules (see Chapter 2).
3.3.4 Quantitative evaluation of excimer fluorescence
By combining lifetime data with steady state spectra, we can obtain an approximation of the

















Molar excess of unlabeled daptomycin
PC/PG
PC
Figure 3.5 Effect of unlabeled daptomycin on the extent of excimer formation by perylene-
daptomycin. Perylene-daptomycin (2.5 µM) was mixed with unlabeled daptomycin at the molar
ratios indicated and incubated with DMPG/DMPC or DMPC liposomes with 6 and 200 mM of cal-
cium, respectively. The change in fluorescence is represented the ratio of emission at 521 nm over
that at 482 nm; a higher ratio indicates a greater extent of excimer formation.
monomer. The calculation, which is detailed in Section 3.2.6, yields the monomer and excimer
spectra shown in Figure 3.6.
The quantum yield of the excimer, relative to that of the monomer, is 0.35. On PC/PG
membranes, the observed excimer emission corresponds to less than 90% of all excitation
events. If we neglect excimer emission due to collisional encounters of the few remaining
monomers, we can infer that more than 90% of all daptomycin molecules are now located in
oligomers. Considering that some excited perylene molecules will emit monomer fluorescence
even when placed in the vicinity of other perylene molecules, the extent of oligomer formation
may well be even higher.
At an oligomerization efficiency of 90%, the ratio of emission at 521 nm to that at 482 nm
is 1.35 (Figure 3.3C). This ratio is 0.33 for PC liposomes (Figure 3.3B), on which perylene-
daptomycin emits mostly as a monomer. On bacterial cells (Figure 3.3D), it is 1.16, which
shows that most of the cell-bound perylene-daptomycin have become incorporated into oligo-
mers. Therefore, on suitable membranes, oligomerization of daptomycin approaches or reaches
completion.
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Figure 3.6 Deconvoluted excimer and monomer spectra of perylene-daptomycin on DMPG/DMPC
membranes. The steps involved in the deconvolution are described in Section 3.2.6.
3.3.5 Titration of excimer fluorescence with phosphatidylglycerol
In previous studies (references [77, 86] and Chapter 2), phosphatidylglycerol was used in con-
siderable molar excess over daptomycin, and therefore these experiments did not provide in-
formation on the stoichiometry of the interaction of daptomycin with PG. To examine this
question, we used a mixture of DMPC and DMPG with an excess of dihexanoyl-PC. Mix-
tures of the latter with lipids of typical acyl chain length yield lipid bicelles, which are small,
disk-like lipid aggregates that are suitable as membrane mimetics [49].
The advantage of bicelles over liposomes is twofold. Firstly, suspensions of bicelles are
much less turbid. This allows measurements at higher concentrations of daptomycin and PG,
which will help to drive the reaction between the two toward completion. Secondly, in a bicelle,
both monolayers will be exposed to daptomycin. In contrast, with liposomes, only the outer
monolayer may be accessible. Previous observation of membrane fusion induced by daptomy-
cin in model liposomes [67] suggests that the membrane continuity may be disrupted, and both
monolayers may be accessible to daptomycin in this system also. On the other hand, membrane
fusion did not go to completion. In addition, no morphological discontinuities were observed
in cell membranes of daptomycin-treated bacteria by electron microscopy [27], suggesting that
the inner monolayer may not or only incompletely be accessible to daptomycin. The use of
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Figure 3.7 Titration of excimer formation with DMPG. Perylene-daptomycin was incubated with
dihexanoyl-PC (20 mM) and calcium (1 mM). A suspension of DMPC/DMPG liposomes was added
in a stepwise fashion, and the perylene fluorescence emission recorded after each addition. The
increment in the ratio of the emissions at 521 nm and at 482 nm is plotted as a function of the molar
ratio of PG to daptomycin. The curve represents a fit to the law of mass action, and the straight
lines represent the tangents of the fit curve at zero and infinity, respectively.
Figure 3.7 shows the titration of 100 µM perylene-daptomycin, in 20 mM dihexanoyl-PC
and 1 mM calcium, with a mixture of dimyristoyl-PC and dimyristoyl-PG. Excimer formation
is monitored as the ratio of fluorescence intensities at wavelengths 521 nm and 482 nm. It can
be seen that the extent of excimer formation, and thus oligomerization, approaches saturation
after addition of a stoichiometric amount of phosphatidylglycerol.
3.4 DISCUSSION
In this study, we synthesized pyrene-daptomycin and perylene-daptomycin and used the latter
to characterize the oligomerization of daptomycin on membranes. The perylene moiety was
introduced into daptomycin by substituting it for the normal decanoyl chain. Considering the
substantial bulk that is added to the molecule by this modification, the fact that the antimicro-
bial activity is reduced no more than threefold is quite remarkable, as is the observation that
the introduction of pyrene caused no measurable decrease in activity at all. These observa-
tions are, however, in line with a previous study on a variety of acyl analogues, which revealed
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only minor changes to the antibacterial activity, as long as the overall hydrophobic character
of the acyl chain was preserved [33]. While the spectral overlap between pyrene and kynure-
nine prevented the observation of pyrene excimer fluorescence, perylene excimers could be
observed and used to characterize the oligomerization of daptomycin. The perylene excimer
fluorescence indicated the formation of daptomycin oligomers on both liposomes and bacte-
rial cells. In liposomes, oligomerization correlates with the presence of phosphatidylglycerol.
These findings are entirely consistent with those obtained using fluorescence energy transfer
(see Chapter 2).
Beyond this confirmation, the use of perylene-daptomycin provides significant additional
insights that could not be inferred from previous experiments. The first novel observation
is the formation of daptomycin oligomers on live bacterial cells. Secondly, using perylene-
daptomycin, the extent of oligomerization could be measured. This extent exceeds 90% on
model membranes that contain 50% DMPG, and it is only slightly lower on bacterial mem-
branes. This high extent of oligomerization supports the notion that it is the oligomer that
causes the bactericidal effect.
Thirdly, the formation of perylene excimers shows that, in the oligomer, the N-terminal
acyl chains interact directly with one another. Direct interaction of the daptomycin peptide
moieties within the oligomer was previously inferred from the self-quenching of NBD-labels
that had been attached to their unique ornithine residues (Chapter 2). Taken together, these
two points of mutual interaction suggest that neighboring oligomer subunits are aligned in a
parallel fashion, or form an acute angle with one another.
The fourth novel finding reported here is that daptomycin oligomerization is driven by a
stoichiometric interaction with phosphatidylglycerol. This result suggests that PG interacts
with daptomycin directly and specifically, rather than indirectly through influencing bulk prop-
erties of the membrane such as charge or lateral phase segregation. Enhanced conversion of PG
to lysyl-PG by bacterial cells has been reported as a mechanism of partial resistance to dapto-
mycin [52, 53]. Against this background, the observed stoichiometric interaction lends further
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support to the hypothesis that PG-mediated oligomerization is essential for the bactericidal
effect of daptomycin.
In summary, the current study provides significant new insights into the interaction of dap-
tomycin with itself and with membrane lipids. At the same time, this study is the first one
to use perylene excimer fluorescence for the characterization of peptide or protein oligomer-
ization. The results provided here illustrate that perylene should be a valuable tool wherever




The subunit stoichiometry of the daptomycin oligomer
4.1 INTRODUCTION
The lipopeptide daptomycin is an important reserve antibiotic for the treatment of infections
by otherwise resistant strains of Gram-positive bacteria such as Staphylococcus aureus and
Enterococcus faecalis [16, 23, 83]. Its bactericidal effect involves membrane depolarization
due to permeabilization for potassium ions [125].
In the preceding chapters of this thesis, daptomycin was shown to form oligomers on bac-
terial membranes and on liposome membranes containing phosphatidylglycerol. Oligomer-
ization is dependent on calcium. The requirements of oligomerization for both calcium and
phosphatidylglycerol mirror those of bactericidal action [10], which suggests that the oligomer
The results presented in this chapter have been published in: “Estimation of the subunit stoichiometry of the
membrane-associated daptomycin oligomer by FRET”, by Muraih, J.K. and Palmer, M. (2012), Biochim Biophys
Acta 1818:1642-7.
Authors’ contributions: The experiment depicted in Figure 4.6 was performed by J. Pogliano. All other experi-
ments were performed by the thesis author. The Python program that implements the numerical simulation shown
in Figure 4.5 was written by M. Palmer.
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forms a functional membrane lesion, as is the case with many other membrane-permeabilizing
peptides and proteins.
At high concentrations and in the presence of calcium, daptomycin also undergoes oligo-
merization in solution. Such oligomers have been structurally characterized by NMR and by
density gradient centrifugation, and they reportedly consist of 14–16 subunits [61]. On the
other hand, the action of daptomycin has also been compared to that of cationic antimicrobial
peptides, many of which do not form discrete oligomers but rather follow the carpet model of
membrane destabilization [120]. In the current study, we therefore set out to determine whether
the membrane-associated oligomer has a defined subunit stoichiometry.
Daptomycin contains several non-standard amino acid residues. One of these, kynurenine,
exhibits an experimentally useful intrinsic fluorescence that responds with a significant gain in
quantum yield to membrane interaction [77]. Another one, ornithine, carries the molecule’s
single free amino group. Derivatization of this ornithine residue can be used to prepare flu-
orescent derivatives such as NBD-daptomycin, which retains antibacterial activity and forms
hybrid oligomers with unlabeled daptomycin (Chapter 2). In NBD-daptomycin, kynurenine
fluorescence is entirely suppressed due to fluorescence resonance energy transfer (FRET) from
kynurenine to NBD. Moreover, in mixed oligomers, FRET also occurs between unlabeled dap-
tomycin and NBD-daptomycin. The experimental approach used here to determine the subunit
stoichiometry of the membrane-bound oligomer consists of a quantitative analysis of the latter
effect. The results suggest that the membrane-associated oligomer is smaller and structurally
different from the oligomer observed in solution.
4.2 MATERIALS AND METHODS
4.2.1 Preparation of liposomes and daptomycin derivatives
Liposomes consisting of an equimolar mixture of DMPC and DMPG were prepared as de-
scribed in Section 2.2. NBD-daptomycin and perylene-daptomycin was prepared as described
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as in Section 2.2 and 3.2.1, respectively. Phospholipids were obtained from Avanti Polar Lipids
Inc., and unlabeled daptomycin was provided by Cubist Pharmaceuticals.
4.2.2 Fluorescence measurements
Samples contained sample buffer (HEPES 20 mM, 150 mM NaCl, pH 7.4), LUV (250 µM
total lipid), calcium chloride (6 mM), and either perylene-daptomycin or daptomycin and
NBD-daptomycin in various proportions and total concentrations. Steady state fluorescence
emission spectra were obtained on a PTI QuantaMaster 4 instrument. For daptomycin and
NBD-daptomycin, the excitation wavelength was 365 nm, and emission was recorded between
400 and 600 nm. For perylene-daptomycin, the excitation wavelength was 430 nm, and emis-
sion was recorded from 440 nm to 600 nm. Excitation and emission slit widths were adjusted
to keep the maximal emission recorded below 106 counts/s; this latter value was determined to
be within the linear range of the instrument’s response.
4.2.3 Determination of the corrected relative kynurenine fluorescence of daptomycin in
mixed oligomer samples
The purpose of the experiments performed here is the quantitation of FRET between kynure-
nine in unlabeled daptomycin and NBD in NBD-daptomycin that occurs within hybrid oligo-
mers of the two species. To this end, it is necessary to measure the kynurenine fluorescence of
unlabeled daptomycin molecules within oligomers that have formed from mixtures of dapto-
mycin with NBD-daptomycin, relative to the fluorescence of the same number of daptomycin
molecules within oligomers formed without NBD-daptomycin, and corrected for FRET that
will occur between pure daptomycin oligomers and NBD-daptomycin-containing oligomers.
Mixtures of daptomycin and NBD-daptomycin, in various proportions as indicated in the
Results section, were prepared and added at a combined final concentration of 10 µM to li-




To correct for FRET between (as opposed to within) oligomers, 4 µM unlabeled dapto-
mycin was then added to the same sample and was again allowed to oligomerize for 180 s,
and the kynurenine fluorescence was read again. The rationale for this calibration procedure







I2 V2V1 − I1
￿
(4.1)
In equation 4.1, Fr is the relative kynurenine fluorescence, and d1 and d2 are the molar amounts
of donor (unlabeled daptomycin) added in the first and second steps, respectively. I0, I1 and I2
are the emission intensities at 445 nm of a liposome blank, and of the oligomer sample after
the first and second addition of daptomycin, respectively. V1 and V2 are the sample volumes
before and after that addition, respectively; the term V2V1 corrects for the dilution caused by the
second addition of daptomycin, which amounted to 4 % of the sample volume.
4.2.4 Numerical simulation of hetero-oligomer formation
The simulation shown in Figure 4.5 was implemented as a Python program. The code of the
program, with explanations, is contained in the supplementary file to reference [101].
4.3 RESULTS
4.3.1 Rationale of the overall experimental approach
The experimental approach used in this study is based on fluorescence resonance energy trans-
fer (FRET) between the kynurenine in unlabeled daptomycin and NBD-daptomycin in hybrid
oligomers. FRET involves the kynurenine residue in unlabeled daptomycin as the donor, and
the NBD moiety of NBD-daptomycin as the acceptor. We made the following assumptions:
1. All daptomycin oligomers have the same number of subunits, n.
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2. Conversion of monomeric daptomycin to oligomers is quantitative on the time scale of
the experiment.
3. When native daptomycin and NBD-daptomycin are mixed before application to mem-
branes, they will form oligomers randomly, without any positive or negative mutual dis-
crimination.
4. In hybrid oligomers, the kynurenine fluorescence of all unlabeled daptomycin molecules
is completely quenched by FRET. Therefore, any remaining kynurenine fluorescence
originates from oligomers that consist of unlabeled daptomycin only.
5. Oligomers are stable on the time scale of the experiment.
Let d be the fraction of native daptomycin in a mixture with NBD-daptomycin (whose
fraction is 1− d). After this mixture has undergone oligomerization according to conditions
1 and 3, the fraction of oligomers that contain only native daptomycin subunits but no NBD-
daptomycin will be dn. Then, the fraction D of all native daptomycin molecules from the





According to assumption 4, only the oligomers represented by D will emit observable kynure-
nine fluorescence. Therefore, the corrected relative kynurenine fluorescence Fr of a given
amount of daptomycin that was mixed with NBD-daptomycin before oligomerization, as de-
fined in equation 4.1, equals D. Substituting Fr for D in equation 4.2 and solving, n yields




Therefore, we can obtain the subunit stoichiometry of the oligomer by comparing the kynure-
nine fluorescence of mixed oligomers to that of pure native daptomycin oligomers.
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In the following, we will first present some experiments that test the assumptions underly-
ing the experimental approach, followed by the experiments to measure the oligomer subunit
stoichiometry.
4.3.2 Kinetics and linear range of the fluorescence signal
Interaction of daptomycin with membranes causes a steep increase in the fluorescence emission
of its single kynurenine residue [77]. Figure 4.1A shows the time course of kynurenine fluo-
rescence after addition of daptomycin to PC/PG liposomes and calcium. The increase in the
fluorescence signal is rapid and largely completed after 300 s. While the fluorescence increase
suggests that the kynurenine residue has entered a more hydrophobic environment, such as the
apolar interior of a lipid membrane, it may under certain conditions also be observed in the ab-
sence of oligomerization (see Section 2.3.3) and therefore does not prove that oligomerization
has indeed occurred.
Oligomerization itself can be monitored with perylene-daptomycin by way of concomitant
formation of perylene excimers (see Chapter 3). The fluorescence of perylene-daptomycin at
560 nm is predominantly due to excimers. Figure 4.1B shows that, as with the kynurenine
fluorescence, the perylene excimer fluorescence develops and stabilizes very rapidly after the
addition of perylene-daptomycin to liposomes and calcium. Therefore, oligomerization pro-
ceeds rapidly and reaches completion on the time scale of the experiment.
Figure 4.1C shows that the kynurenine emission signal is linear across the range of con-
centrations and under the measurement conditions of the experiment. Thus, the kynurenine
emission can be used to measure the amount of fluorescence-emitting oligomers.
4.3.3 Kynurenine fluorescence of daptomycin in the presence of NBD-daptomycin
When daptomycin and NBD-daptomycin are mixed and then added to membranes, the kynure-
nine fluorescence of the unlabeled species is strongly suppressed (Figure 4.2A). The strong
reduction of the kynurenine emission in this sample suggests that most unlabeled daptomycin
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Figure 4.1 Time course and linear range of daptomycin fluorescence responses to interaction with
liposomes. A: Time course of kynurenine fluorescence of 10 µM native daptomycin upon addition
of PC/PG liposomes (250 µM total lipid) and calcium (6 mM) at time = 0. The small initial lag is
caused by the shutter of the instrument. B: Time course of perylene fluorescence (λex = 430 nm,
λem = 560 nm) of 2.5 µM perylene-daptomycin to liposomes and calcium as before. The emission
at 560 nm is mostly caused by excimers (see Chapter 3), indicating that oligomer formation is
instantaneous. C: Linear range of kynurenine fluorescence upon addition of native daptomycin to


















































Figure 4.2 FRET within and between daptomycin oligomers. A: Fluorescence emission spectra of
2.4 µM daptomycin only, and of daptomycin (2.4 µM) plus NBD-daptomycin (0.9 µM), pre-mixed
before addition to liposomes and calcium or added sequentially to the latter, with incubation for 3
min between the additions of the two species. Solid lines are spectra taken 5 min after sample
preparation, and dashed lines are spectra acquired after an additional incubation for 10 min after
the first measurement. The absence of an intensity decrease in the sequentially prepared sample
indicates that the donor and acceptor oligomers remain distinct and stable on the time scale of
the experiment. B: Kynurenine fluorescence intensity of samples containing native daptomycin and
NBD-daptomycin at 2:1 molar ratio, and sequentially incubated with liposomes and calcium, at 250
µM total lipid and the indicated ratio of lipid to total daptomycin, relative to samples containing the
same amount of native daptomycin but no NBD-daptomycin.
has indeed been incorporated into hybrid oligomers (assumption 3), and that its kynurenine
fluorescence is effectively quenched within these hybrids (assumption 4).
Figure 4.2A also shows the fluorescence of a sample that was prepared sequentially, such
that unlabeled daptomycin was applied to the membranes first, and NBD-daptomycin was ap-
plied 3 minutes later. Under these conditions, daptomycin and NBD-daptomycin should form
oligomers separately. Here, the kynurenine signal is higher. It remains virtually unchanged
after 10 min, indicating that the two oligomer species have remained separate and have not
rearranged into hybrid oligomers; thus, individual oligomers are stable on this time scale (as-
sumption 5).
On the other hand, the kynurenine fluorescence of the sequentially prepared sample in Fig-
ure 4.2A is below that of a sample containing no NBD-daptomycin at all. This indicates that,
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in the sequentially prepared sample, the kynurenine fluorescence of the daptomycin-only oli-
gomers is partially quenched by FRET to NBD-daptomycin oligomers in the vicinity. Raising
the ratio of lipid to daptomycin reduces but does not eliminate FRET between oligomers (Fig-
ure 4.2B).
For our intended use of equation 4.3, we need to determine the FRET that occurs within
hybrid oligomers, as opposed to between them. According to assumptions 2 and 5, we can
correct for FRET between oligomers experimentally by adding a fixed quantity of unlabeled
daptomycin to the same sample after the hybrid oligomers have been formed. The principle of
this correction method is illustrated in Figure 4.3A; its details are given in Section 4.2.3.
The experiments described so far support our assumptions 2 and 5. Assumptions 3 and
4 are supported to a degree: Hybrid oligomer formation and strong quenching by FRET are
evident, but perfect randomness of oligomerization and quantitative FRET are hard to prove,
as is the uniformity of the oligomer subunit stoichiometry (assumption 1). For now, these latter
assumptions may be taken as working hypotheses; we will revisit them in the Discussion.
4.3.4 Kynurenine fluorescence in hybrid oligomers formed on membranes
In the experiments shown in Figure 4.4, NBD-daptomycin was combined with unlabeled dap-
tomycin at various molar ratios; the total of both species was kept constant at 10 µM. The
mixtures were added to PC/PG membranes (250 µM total lipid) and calcium (6 mM). The
kynurenine fluorescence of the ensuing oligomers was measured and corrected for FRET be-
tween oligomers as described above, and the oligomer subunit stoichiometry, n, was calculated
using equation 4.3. The calculated individual values for n vary between 5.7 and 7.5.
In sum, the results shown in Figure 4.4 support the notion that daptomycin forms oligomers
with approximately six to seven subunits on membranes. This interpretation must be qualified








































Figure 4.3 Illustration of the experimental approach used to measure oligomer subunit stoichiom-
etry (A), and of hypothetical oligomer structures (B). A: When a mixture of donor (D; native dap-
tomycin) and acceptor molecules (A; NBD-daptomycin) is applied to membranes, they randomly
combine into oligomers. The fraction D1 of donor monomers that become incorporated into pure
donor oligomers is related to the number of oligomer subunits according to equation 4.2. In order to
determine D1 from the donor fluorescence, the latter must be corrected for FRET between donor-
only oligomers and acceptor-containing oligomers in the vicinity. To this end, a second sample
containing native daptomycin only is added subsequently. These molecules will all be converted to
donor-only oligomers; that is, D2 = 1. At the same time, they will be quenched by FRET to acceptor-
containing oligomers to the same extent as the oligomers represented by D1. Their fluorescence
intensity can therefore be used to calibrate the determination of D1 from the donor fluorescence
measured after the first step. B: Hypothetical daptomycin oligomer structures. It is presently un-
known whether daptomycin becomes embedded only into the outer monolayer (top) or into both
monolayers (bottom). In the latter case, it is conceivable that the distance between two subunits
embedded in different monolayers exceeds the Förster radius for FRET between kynurenine and
NBD (2.7 nm). In this case, the actual subunit stoichiometry may be up to twice the value obtained
by the FRET experiments presented in this study.
4.4 DISCUSSION
This study aimed at determining the subunit stoichiometry of the membrane-associated dapto-
mycin oligomer. The approach taken here is similar to that used previously for measuring the
number of lipid II molecules that are incorporated into the transmembrane pores formed by the
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Figure 4.4 Determination of oligomer subunit stoichiometry by FRET. A: Kynurenine fluorescence
intensities of 4 individual experiments, each performed at 4 different donor/acceptor ratios. The
fluorescence intensities were corrected according to equation 4.1. The curves represent theoretical
values calculated according to equation 4.2. B: Subunit stoichiometries calculated using equation
4.3 from the values shown in A (averages ± standard deviation).
lantibiotic1 nisin [56]. In both cases, random mixing of a fluorescently labeled derivative with
the native species was assumed, and the oligomer subunit stoichiometry was extracted from the
probability of mutual interaction of two fluorophore molecules. Both approaches also assume
the interaction between two fluorophore molecules to occur with equal and complete efficiency,
regardless of their respective positions and distance within the oligomer. In Ref. [56], the inter-
action in question was the formation of pyrene excimers, whereas FRET was employed in the
current study. Heteromer analysis using FRET has also previously been used to characterize
the dimeric nature of membrane-associated gramicidin [138].
Both excimer formation and FRET are sensitive to distance. In the case of FRET, the
distance dependency is given by the Förster radius, R0, which for unlabeled daptomycin and
NBD-daptomycin was previously estimated to 2.7 nm (Chapter 2). The thickness of a lipid
bilayer is on the order of 4 nm. While the fluorescence changes of kynurenine in native dap-
tomycin [77] and of NBD in NBD-daptomycin suggest that both fluorophores insert into the
membrane, it is possible that they both remain close to the membrane surface. It is currently
1The so-called “lantibiotics” are antibiotics that contain one or more lanthionine residues. Lanthionine con-
tains two alanine residues linked by a thioether bridge.
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unknown whether a single daptomycin oligomer interacts with one or both membrane leaflets.
If indeed it interacts with both, subunits located in opposite leaflets may be beyond the reach
of mutual FRET (see Figure 4.3B). The apparent oligomer stoichiometry obtained with the
present method would then reflect the number of subunits in only one of the two monolayers,
and the total number of subunits might in fact be twice as high. To resolve this question, it
would be desirable to use probes that provide a greater effective R0; however, several other
fluorescent derivatives that we tested showed a significant reduction in their specific activity,
which suggests that their oligomerization may be impaired, too, and therefore that they may
not be able to randomly co-oligomerize with native daptomycin.
The extraction of the subunit stoichiometry from FRET within hybrid oligomers requires
correction for FRET occurring between donor-only and acceptor-containing oligomers. In
principle, it should be possible to separate oligomers from one another by dilution, that is,
by making the ratio of daptomycin to lipid very small. However, this approach is not feasi-
ble in practice, because the fluorescence intensity of kynurenine is low; its molar extinction
coefficient is 4000, and its quantum yield is only 0.04 (see Chapter 2). Furthermore, at high
lipid concentration and in the presence of calcium, the PG-containing liposomes become very
turbid, which interferes with the accurate measurement of fluorescence intensities. It was there-
fore necessary to correct for, rather than physically eliminate, FRET between oligomers.
Our fluorescence correction procedure assumes that all daptomycin oligomers are dis-
tributed evenly in the membrane, or alternatively that the native daptomycin applied in the
second step will be distributed in the membrane in the same manner as the mixture of the na-
tive and NBD-daptomycin that was applied in the first step. In this context, it is noteworthy that
the extent of FRET between oligomers (cf. Figure 4.2B) is greater than predicted for randomly
distributed donors and effectors by the pertinent formula given by Wolber and Hudson [144]
with the parameters of our system (R0 = 2.7 nm, surface area of 0.7 nm2 per lipid molecule).
It is known that acidic phospholipids within mixed membranes tend to cluster in the pres-
ence of calcium, and this tendency is further promoted by proteins and peptides that bind to
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Figure 4.5 Numerical simulation of oligomerization with varying bimolecular rate constants for the
incorporation of donor and acceptor monomers into growing oligomers. The oligomer is assumed
to contain 6 subunits. The bimolecular rate constant kA, which controls the addition of an acceptor
monomer to an incomplete oligomer, was held at 1 in each case, whereas the rate constant kD,
which controls the addition of a donor monomer to an incomplete oligomer, was varied between 0.1
and 10. The program used to perform the calculation is mentioned in the supplementary file of the
Ref. [101]. A: For each combination of rate constants, the fraction d of donors that are incorporated
into donor-only oligomers is plotted as a function of the fraction of donor monomers d in the initial
mixture (compare equation 4.2). B: The apparent subunit stoichiometries that would be inferred
from the data shown in A according to equations 4.2 and 4.3 are plotted as functions of d.
them multivalently [142]. With bacterial cells, daptomycin clusters have indeed been observed
on bacterial membranes. Importantly, however, in those experiments, two samples of dapto-
mycin that carried two different labels and were added to the same cells at different times were
found enriched and superimposed in the very same locations on the membrane (J. Pogliano,
personal communication; see Figure 4.6). We assume that the same happens on our liposome
membranes.
In the previously obtained NMR structure of daptomycin in water [9], the diameter of the
peptide moiety, in a plane perpendicular to the extended fatty acyl chain, ranges from 0.8 to 1.2
nm. Therefore, even if we confine the consideration to subunits within the same monolayer,
it is conceivable that the cumulative diameter of the oligomer subunits may exceed the range
within which FRET can be assumed to be quantitative, as was done in the present study. In
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Figure 4.6 Dual labelling of bacterial cells with two colors of two labeled derivatives of Daptomycin.
In sequential additions, Dap-Bodipy (16 µg/ml) was incubated with cells for five minutes and then
Dap-Rh (16 µg/ml) was added for five more minutes. Excess labelled daptomycin was removed by
washing the cells three times in LB. Cells were stained with DAPI (blue) to visualize the nucleoids.
The same field of cells is shown in each panel. Experiment performed by J. Pogliano.
this context, however, it is interesting to note that, upon prolonged exposure of daptomycin
oligomers that were formed on membranes to 10 mM of the detergent CHAPS, an apparent
oligomer subunit stoichiometry of up to 15 was observed. This finding suggests that within the
membrane—or, as discussed above, within a membrane monolayer—it is not the R0 that limits
the extent of FRET but rather the actual number of subunits present. (CHAPS was also found
to induce rapid destabilization of oligomers, as evident from scrambling of donor and acceptor
subunits, and therefore CHAPS-solubilized samples cannot be considered a valid model of the
membrane-associated state of daptomycin.)
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Another caveat concerning the method employed in this study concerns the relative rates of
oligomer incorporation of the donor and the acceptor; these rates cannot currently be measured
accurately. Figure 4.5 shows simulated data to illustrate what happens if the donor oligomerizes
either more rapidly or more slowly than the acceptor. While native daptomycin and NBD-
daptomycin have the same specific activity, it still seems possible that their rates of oligomer
incorporation may be slightly different, which may then cause the estimated number of subunits
to deviate from the true value.
Our analysis is also based on the assumption of uniform oligomer subunit stoichiometry.
While our data do not provide direct evidence for or against this assumption, it seems to fit
with the previously reported selective and specific nature of the permeability lesion caused
by daptomycin [125, 2]. Less selective and possibly dose-dependent leakage of larger marker
molecules might be expected in the case of inhomogeneous subunit stoichiometries of oligo-
mers and associated membrane defects.
In sum, the results of our study indicate that the membrane-associated daptomycin oligo-
mer contains approximately six to seven subunits. Whether this number applies to the en-
tire oligomer or rather to a part of it that is embedded in one of the two membrane leaflets
remains to be determined. In either case, the findings support the notion that daptomycin
acts through the formation of oligomers of discrete size, rather than through detergent-like or
carpet-mode wholesale membrane disruption. This conclusion is in line with the previously
observed absence of morphological disruption of bacterial cell membranes exposed to dapto-
mycin [27], as well as with the selective inhibition of membrane potential-dependent, but not




Summary and future research work
5.1 SUMMARY
In this thesis, I have investigated the mode of action of the lipopeptide antibiotic daptomycin.
Chapter 2 focused on studying the oligomerization of daptomycin on liposomal and bac-
terial membranes as part of the mechanism of its antibacterial activity against Gram-positive
bacteria. The previous studies only assumed that oligomerization of daptomycin molecules on
membranes may be required for the bactericidal activity of daptomycin, but did not provide
any experimental evidence. In our study, this evidence was obtained by using FRET, which oc-
curred between kynurenine in native daptomycin as the donor and NBD in NBD-daptomycin as
the acceptor. Oligomerization was also evident from the self-quenching of NBD-daptomycin
fluorescence on membranes. The oligomers were stable on a time scale of several hours. They
were detected on liposomal membranes containing phosphatidylglycerol (PG), combined with
either phosphatidylcholine (PC) or phosphatidylethanolamine (PE) plus cardiolipin (CL), as
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well as on membrane vesicles prepared from Bacillus subtilis (ATCC 6633) cells. No oligo-
merization was observed on membranes lacking PG. Therefore, we showed that oligomeriza-
tion has the same requirements for Ca 2+ and for PG that also applies to antibacterial activity.
This strongly suggests that oligomerization is important for antibacterial action.
It was previously observed by using NMR that daptomycin can oligomerize in solution, and
it was proposed that this step was integral to the mode of action of daptomycin [9]. However,
those studies were performed at relatively high daptomycin concentrations, in the millimolar
range. In contrast, our studies were conducted with fluorescence, which is more sensitive than
NMR and permits daptomycin molecules to be observed under conditions and concentrations
similar to MIC, both in solution and on membranes. Using a daptomycin derivative fluores-
cently labeled with Alexa Fluor 350, we showed that oligomerization did not occur in solution
at daptomycin concentrations similar to MIC. Therefore, daptomycin most likely interacts with
the membrane as a monomer and does not need to undergo aggregation or oligomerization in
solution in order to acquire antibacterial activity.
The work described in Chapter 3 served to further characterize the membrane-associated
daptomycin oligomer by using excimer fluorescence. An excimer, or excited dimer, is a com-
plex that forms from one perylene fluorophore molecule that is in the excited state and another
one in the ground state [78]. For this purpose, daptomycin was labeled with perylene instead
of pyrene, which is more commonly used for excimer studies. This was necessary because
the excitation energy of pyrene was almost quantitatively transferred to kynurenine by FRET,
preventing the observation pyrene excimers. In contrast, perylene absorbs and emits at longer
wavelengths than pyrene [66], and therefore was unaffected by FRET.
Under conditions resembling those used in the previous FRET experiments, oligomer for-
mation of perylene-daptomycin was evident through excimer fluorescence on both liposomes
and bacterial cells. Since excimer formation involves direct contact of the two labels in ques-
tion, it is highly sensitive to distance. The observation of excimer fluorescence thus imposes
a stricter constraint on the distance of the interaction than that implied by the observation of
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FRET. Since perylene had been introduced into the fatty acyl residue position of daptomy-
cin, the observation of excimer fluorescence indicates that the fatty acyl residues of adjacent
subunits of the oligomer are interacting directly with one another.
Perylene-daptomycin excimer fluorescence was also used to directly demonstrate the ef-
ficient formation of daptomycin oligomers on intact bacterial cells. Perylene-daptomycin re-
tained its antibacterial activity at a slightly reduced level. This gives further support to the
notion that the oligomeric form of daptomycin is responsible for the antibacterial effect.
It is also noteworthy that our study is the first one to use perylene excimer fluorescence for
the characterization of peptide or protein oligomerization. It therefore illustrates that perylene
excimer fluorescence is useful in the experimental study of biochemical systems.
In a lipid bicelle system, we found that excimer fluorescence could be titrated with phos-
phatidylglycerol. The result showed that daptomycin oligomerization is driven by a stoi-
chiometric interaction with phosphatidylglycerol (PG). Therefore, a single molecule of phos-
phatidylglycerol is adequate to convert daptomycin to a conformation that is proficient for
oligomerization. This result confirms that PG interacts with daptomycin directly and specifi-
cally. This is consistent with but goes beyond the previous conclusion from FRET experiments
(Chapter 2).
In Chapter 4, we tried to determine the subunit stoichiometry of the membrane-associated
daptomycin oligomer. From the extent of energy transfer observed in such hybrid oligomers
of labeled and unlabeled daptomycin, we calculated that the oligomer contains approximately
6 to 7 subunits. This calculation is based on the assumptions that all oligomers have the same
number of subunits, and that donor and acceptor co-oligomerize in a perfectly random manner.
We cannot exclude the possibility that the oligomer spans both membrane monolayers in a
manner that reduces or prevents FRET between subunits embedded in opposite monolayers; in
this case, the actual number of subunits might be up to twice as high as apparent from our ex-
periments. While the number of subunits is therefore not yet known precisely, our findings do
indicate a relatively small size of the daptomycin oligomer; this agrees with a relatively selec-
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tive membrane permeabilization and with the absence of membrane discontinuities observable
by electron microscopy shown in earlier studies.
In conclusion, the work in my thesis has shown that daptomycin forms small, stable oligo-
mers on bacterial membranes. Oligomerization depends on a stoichiometric interaction with
phosphatidylglycerol and very likely is required for the antibacterial effect of daptomycin.
These findings significantly enhance our understanding of daptomycin’s mode of action.
5.2 FURTHER RESEARCH WORK
The findings in my thesis raise additional questions that need to be addressed by future re-
search.
5.2.1 Causative role of oligomerization in bactericidal action
While this thesis has provided solid evidence for a close correlation of oligomer formation
on membranes and bactericidal action, a causative role has not been unequivocally proven. A
possible approach to this question might be the use of mixtures of wild type daptomycin and a
functionally impaired variant; a study cited earlier [104] has provided several such molecules.
If oligomerization is not important, the mixtures should display strictly additive activity. On
the other hand, if the phenotype of one species were to dominate the other, this would indicate
that the mutual interaction of several molecules is critical for the activity of daptomycin.
5.2.2 Contribution of the negatively charged phospholipids other than PG to daptomycin
binding, oligomerization, and bactericidal action
Binding and oligomerization of daptomycin on membranes require Ca2+ and correlate with the
presence of phosphatidylglycerol (see Chapter 2). However, it has not yet been determined
how other negatively charged phospholipids may affect the interaction of daptomycin with
membranes.
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Apart from PG, the most abundant negatively charged phospholipid in bacterial membranes
is cardiolipin. We performed some initial experiments on cardiolipin, which showed that it
facilitates calcium-dependent binding of daptomycin molecules to the membrane. However,
there is no obvious evidence regarding formation of oligomers on membranes composed from
PC and cardiolipin in ratio 4:1. The effect of cardiolipin on the antibacterial effect of dapto-
mycin remains to be determined.
5.2.3 Functional characterization of the membrane defect
In addition to the structure, the functional properties of the membrane defect also remain in-
completely understood. Exposure of Staphylococcus aureus to daptomycin has been reported
to cause release of calcein from the cells, while the DNA-binding dye ToPro3 remains ex-
cluded [27]. The selectivity of the membrane defect for molecules differing in size and charge
deserves to be more completely characterized.
5.2.4 Analysis of oligomer structure on membranes by NMR
The relatively small size of the membrane-associated daptomycin oligomer suggests that it
should be feasible to determine its structure by NMR, and Dr. Dieckmann’s group has begun
such experiments. NMR in solution is, however, hampered by sample aggregation, which
is due to the simultaneous requirement for Ca2+ and PG. Solid state NMR may be another
possibility, and some initial experiments have been run by Dr. Ladizhansky at the University




Chapters 2–4 of this thesis contain text and figures that have been published as separate papers
in Biochimica et Biophysica Acta. The text and figures are here included with permission; the























































































































































































































































































































































































































































































































































































































































































































































[1] R.L. Akins and M.J. Rybak. In vitro activities of daptomycin, arbekacin, vancomycin,
and gentamicin alone and/or in combination against glycopeptide intermediate-resistant
Staphylococcus aureus in an infection model. Antimicrob Agents Chemother,
44(7):1925, 2000.
[2] WE Alborn Jr, NE Allen, and DA Preston. Daptomycin disrupts membrane potential
in growing Staphylococcus aureus. Antimicrob Agents Chemother, 35(11):2282–2287,
1991.
[3] J.D. Alder. Daptomycin: a new drug class for the treatment of gram-positive infections.
Drugs Today, 41(2):81–90, 2005.
[4] NE Allen, WE Alborn Jr, and JN Hobbs Jr. Inhibition of membrane potential-dependent
amino acid transport by daptomycin. Antimicrob Agents Chemother, 35(12):2639–2642,
1991.
[5] NE Allen, JN Hobbs, and WE Alborn Jr. Inhibition of peptidoglycan biosynthesis in
gram-positive bacteria by ly146032. Antimicrob Agents Chemother, 31(7):1093, 1987.
[6] D. Andreu, L. Rivas, et al. Animal antimicrobial peptides: an overview. Biopolymers,
47(6):415–433, 1998.
[7] R.D. Arbeit, D. Maki, F.P. Tally, E. Campanaro, B.I. Eisenstein, et al. The safety and ef-
ficacy of daptomycin for the treatment of complicated skin and skin-structure infections.
Clin Infect Dis, 38(12):1673, 2004.
113
Bibliography
[8] A. Attia and G. Buisson. Advances in Mesopotamian Medicine from Hammurabi to
Hippocrates: Proceedings of the International Conference" Oeil Malade Et Mauvais
Oeil", Collège de France, Paris, 23rd June 2006, volume 37. Brill Academic Pub, 2009.
[9] L.J. Ball, C.M. Goult, J.A. Donarski, J. Micklefield, and V. Ramesh. Nmr structure
determination and calcium binding effects of lipopeptide antibiotic daptomycin. Org
Biomol Chem, 2(13):1872–1878, 2004.
[10] R.H. Baltz. Daptomycin: mechanisms of action and resistance, and biosynthetic engi-
neering. Curr Opin Chem Biol, 13(2):144–151, 2009.
[11] R.H. Baltz, P. Brian, V. Miao, and S.K. Wrigley. Combinatorial biosynthesis of lipopep-
tide antibiotics in streptomyces roseosporus. J. Ind. Microbiol. Biotechnol., 33(2):66–74,
2006.
[12] R.H. Baltz, V. Miao, and S.K. Wrigley. Natural products to drugs: daptomycin and
related lipopeptide antibiotics. Nat Prod Rep, 22(6):717–741, 2005.
[13] F. Baquero and J. Blazquez. Evolution of antibiotic resistance. Trends Ecol Evol,
12(12):482–487, 1997.
[14] A.L. Barry, P.C. Fuchs, and S.D. Brown. In vitro activities of daptomycin against 2,789
clinical isolates from 11 north american medical centers. Antimicrob Agents Chemother,
45(6):1919, 2001.
[15] A. Beiras-Fernandez, F. Vogt, R. Sodian, and F. Weis. Daptomycin: a novel lipopeptide
antibiotic against gram-positive pathogens. Infect Drug Resist, 3:95, 2010.
[16] J.M. Bell, J.D. Turnidge, H.S. Sader, and R.N. Jones. Antimicrobial activity and spec-
trum of daptomycin: results from the surveillance program in australia and new zealand
(2008). Pathology, 42(5):470, 2010.
114
Bibliography
[17] M.L. Bland, S.T. Vermillion, D.E. Soper, and M. Austin. Antibiotic resistance patterns
of group b streptococci in late third-trimester rectovaginal cultures. Am J Obstet Gy-
necol, 184(6):1125–1126, 2001.
[18] M. Boaretti, P. Canepari, M. del Mar Lleò, and G. Satta. The activity of daptomycin on
enterococcus faecium protoplasts: indirect evidence supporting a novel mode of action
on lipoteichoic acid synthesis. Antimicrob Agents Chemother, 31(2):227–235, 1993.
[19] T. Bogdanovich, L.M. Ednie, S. Shapiro, and P.C. Appelbaum. Antistaphylococ-
cal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents
Chemother, 49(10):4210–4219, 2005.
[20] H.G. Boman. Peptide antibiotics and their role in innate immunity. Annu Rev Immunol,
13(1):61–92, 1995.
[21] R.S. Brown, J.D. Brennan, and U.J. Krull. Self-quenching of nitrobenzoxadiazole la-
beled phospholipids in lipid membranes. J Chem Phys, 100:6019, 1994.
[22] P. Canepari, M. Boaretti, M.M. Lleo, and G. Satta. Lipoteichoic acid as a new target
for activity of antibiotics: mode of action of daptomycin (ly146032). Antimicrob Agents
Chemother, 34(6):1220, 1990.
[23] R. Cantón, P. Ruiz-Garbajosa, R.L. Chaves, and A.P. Johnson. A potential role for
daptomycin in enterococcal infections: what is the evidence? J Antimicrob Chemother,
65(6):1126, 2010.
[24] E. Chain, H.W. Florey, A.D. Gardner, N.G. Heatley, M.A. Jennings, J. Orr-Ewing, and
A.G. Sanders. Penicillin as a chemotherapeutic agent. Lancet, 236(6104):226–228,
1940.
[25] S. Chang, D.M. Sievert, J.C. Hageman, M.L. Boulton, F.C. Tenover, F.P. Downes,
S. Shah, J.T. Rudrik, G.R. Pupp, W.J. Brown, et al. Infection with vancomycin-
115
Bibliography
resistant Staphylococcus aureus containing the vana resistance gene. N. Engl. J. Med.,
348(14):1342–1347, 2003.
[26] M.F. Coëffet-Le Gal, L. Thurston, P. Rich, V. Miao, and R.H. Baltz. Complementa-
tion of daptomycin dpta and dptd deletion mutations in trans and production of hybrid
lipopeptide antibiotics. Microbiology, 152(10):2993–3001, 2006.
[27] N. Cotroneo, R. Harris, N. Perlmutter, T. Beveridge, and J.A. Silverman. Daptomycin
exerts bactericidal activity without lysis of Staphylococcus aureus. Antimicrob Agents
Chemother, 52(6):2223–2225, 2008.
[28] FT Counter, NE Allen, DS Fukuda, JN Hobbs, J. Ott, PW Ensminger, JS Mynderse,
DA Preston, CY Wu, et al. A54145 a new lipopeptide antibiotic complex: microbiolog-
ical evaluation. J. Antibiot., 43(6):616, 1990.
[29] G.M. Cragg and D.J. Newman. Natural product drug discovery in the next millennium.
Pharm. Biol., 39(s1):8–17, 2001.
[30] L. Cui, E. Tominaga, H. Neoh, and K. Hiramatsu. Correlation between reduced dapto-
mycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylo-
coccus aureus. Antimicrob Agents Chemother, 50(3):1079, 2006.
[31] T.A. Davies, M.G.P. Page, W. Shang, T. Andrew, M. Kania, and K. Bush. Binding
of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli,
Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. An-
timicrob. Agents Chemother., 51(7):2621–2624, 2007.
[32] B.D. Davis. Mechanism of bactericidal action of aminoglycosides. Microbiol Rev,
51(3):341, 1987.
[33] M. Debono, B.J. Abbott, R.M. Molloy, D.S. Fukuda, AH Hunt, V.M. Daupert, F.T.
Counter, J.L. Ott, C.B. Carrell, L.C. Howard, et al. Enzymatic and chemical modifi-
116
Bibliography
cations of lipopeptide antibiotic a21978c: the synthesis and evaluation of daptomycin
(ly146032). J Antibiot, 41(8):1093, 1988.
[34] M. Debono, M. Barnhart, CB Carrell, JA Hoffmann, JL Occolowitz, BJ Abbott,
DS Fukuda, RL Hamill, K. Biemann, WC Herlihy, et al. A21978c, a complex of new
acidic peptide antibiotics: isolation, chemistry, and mass spectral structure elucidation.
J Antibiot, 40(6):761, 1987.
[35] O. Denis, A. Deplano, C. Nonhoff, M. Hallin, R. De Ryck, R. Vanhoof, R. De Men-
donça, and M.J. Struelens. In vitro activities of ceftobiprole, tigecycline, daptomycin,
and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains
from a national survey of belgian hospitals. Antimicrob Agents Chemother, 50(8):2680–
2685, 2006.
[36] G.J. Domagk. Ein beitrag zur chemotherapie der bakteriellen infection. Dtsch Med
Wochenschr, 61:250–253, 1935.
[37] WL Duax, J.F. Griffin, DA Langs, GD Smith, P. Grochulski, V. Pletnev, and V. Ivanov.
Molecular structure and mechanisms of action of cyclic and linear ion transport antibi-
otics. Pept Sci, 40(1):141–155, 1996.
[38] B.I. Eisenstein, F.B. Oleson, and R.H. Baltz. Daptomycin: from the mountain to the
clinic, with essential help from francis tally, md. Clin Infect Dis, 50(Supplement 1):S10,
2010.
[39] R.M. Epand, S. Rotem, A. Mor, B. Berno, and R.F. Epand. Bacterial membranes as
predictors of antimicrobial potency. J Am Chem Soc, 130(43):14346–14352, 2008.
[40] M. Fallarino. Tibetan medical paintings, 1994.
117
Bibliography
[41] M.A. Fischbach, C.T. Walsh, et al. Assembly-line enzymology for polyketide and
nonribosomal peptide antibiotics: logic, machinery, and mechanisms. Chem. Rev.,
106(8):3468, 2006.
[42] A. Fleming. On the antibacterial action of cultures of a penicillium, with special ref-
erence to their use in the isolation of b. influenzae. Br J Exp Pathol, 10(31):226–36,
1929.
[43] T. Föerster. Intermolecular energy migration and fluorescence. Ann Phys, 2:55–75,
1948.
[44] J.R. Fouts, J.J. Kamm, and B.B. Brodie. Enzymatic reduction of prontosil and other azo
dyes. J Pharmacol Exp Ther, 120(3):291–300, 1957.
[45] R. O. Fox and F. M. Richards. A voltage-gated ion channel model inferred from the
crystal structure of alamethicin at 1.5-a resolution. Nature, 300(5890):325–330, Nov
1982.
[46] TR Frieden, SS Munsiff, G. Williams, Y. Faur, B. Kreiswirth, DE Low, BM Willey,
S. Warren, and W. Eisner. Emergence of vancomycin-resistant enterococci in new york
city. Lancet, 342(8863):76–79, 1993.
[47] L. Friedman, J.D. Alder, and J.A. Silverman. Genetic changes that correlate with
reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents
Chemother, 50(6):2137–2145, 2006.
[48] L.P. Garrod and F. O’Grady. Antibiotic and Chemotherapy. Livingstone, 3 edition, 1971.
[49] K.J. Glover, J.A. Whiles, G. Wu, N. Yu, R. Deems, J.O. Struppe, R.E. Stark, E.A.
Komives, and R.R. Vold. Structural evaluation of phospholipid bicelles for solution-
state studies of membrane-associated biomolecules. Biophys J, 81(4):2163–2171, 2001.
[50] D. Greenwood. Antimicrobial Chemotherapy. Oxford University Press, 4 edition, 2000.
118
Bibliography
[51] J. Grünewald, S.A. Sieber, C. Mahlert, U. Linne, and M.A. Marahiel. Synthesis and
derivatization of daptomycin: a chemoenzymatic route to acidic lipopeptide antibiotics.
J Am Chem Soc, 126(51):17025–17031, 2004.
[52] A.B. Hachmann, E.R. Angert, and J.D. Helmann. Genetic analysis of factors affect-
ing susceptibility of Bacillus subtilis to daptomycin. Antimicrob Agents Chemother,
53(4):1598, 2009.
[53] A.B. Hachmann, E. Sevim, A. Gaballa, D.L. Popham, H. Antelmann, and J.D. Helmann.
Reduction in membrane phosphatidylglycerol content leads to daptomycin resistance in
Bacillus subtilis. Antimicrob Agents Chemother, 55(9):4326, 2011.
[54] R. E W Hancock and A. Patrzykat. Clinical development of cationic antimicrobial pep-
tides: from natural to novel antibiotics. Curr Drug Targets Infect Disord, 2(1):79–83,
Mar 2002.
[55] R.E.W. Hancock. Cationic antimicrobial peptides: towards clinical applications. Expert
Opin. Invest. Drugs, 9(8):1723–1729, 2000.
[56] H.E. Hasper, B. de Kruijff, and E. Breukink. Assembly and stability of nisin-lipid ii
pores. Biochemistry, 43(36):11567–11575, 2004.
[57] MK Hayden, K. Rezai, RA Hayes, K. Lolans, JP Quinn, and RA Weinstein. Develop-
ment of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J
Clin Microbiol, 43(10):5285, 2005.
[58] B. Heinemann, MA Kaplan, RD Muir, and IR Hooper. Amphomycin, a new antibiotic.
Antibiot Chemother, 3:1239–1242, 1953.
[59] J. Hill, J. Siedlecki, I. Parr, M. Morytko, X. Yu, Y. Zhang, J. Silverman, N. Contro-
neo, V. Laganas, T. Li, et al. Synthesis and biological activity of n-acylated ornithine
analogues of daptomycin. Bioorg Med Chem Lett, 13(23):4187–4191, 2003.
119
Bibliography
[60] K. Hiramatsu, H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and FC Tenover. Methicillin-
resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.
J Antimicrob Chemother, 40(1):135–136, 1997.
[61] S.W. Ho, D. Jung, J.R. Calhoun, J.D. Lear, M. Okon, W.R.P. Scott, R.E.W. Hancock,
and S.K. Straus. Effect of divalent cations on the structure of the antibiotic daptomycin.
Eur Biophys J, 37(4):421–433, 2008.
[62] R.D. Hotchkiss and R.J. Dubos. The isolation of bactericidal substances from cultures
of Bacillus brevis. J Biol Chem, 141(1):155, 1941.
[63] V. M. Hughes and N. Datta. Conjugative plasmids in bacteria of the ’pre-antibiotic’ era.
Nature, 302(5910):725–726, Apr 1983.
[64] M.J. Jedrzejas. Pneumococcal virulence factors: structure and function. Microbiol Mol
Biol Rev, 65(2):187–207, 2001.
[65] J. Jeljaszewicz, G. Mlynarczyk, and A. Mlynarczyk. Antibiotic resistance in gram-
positive cocci. Int J Antimicrob Agents, 16(4):473–478, 2000.
[66] PC Johnson and HW Offen. Perylene excimer fluorescence in cyclohexane. Chem Phys
Lett, 18(2):258–260, 1973.
[67] D. Jung, J.P. Powers, S.K. Straus, and R.E.W. Hancock. Lipid-specific binding of the
calcium-dependent antibiotic daptomycin leads to changes in lipid polymorphism of
model membranes. Chem Phys Lipids, 154(2):120–128, 2008.
[68] D. Jung, A. Rozek, M. Okon, and R.E.W. Hancock. Structural transitions as deter-
minants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol,
11(7):949–957, 2004.
[69] T. Kelesidis, R. Humphries, D.Z. Uslan, and D.A. Pegues. Daptomycin nonsusceptible
enterococci: an emerging challenge for clinicians. Clin Infect Dis, 52(2):228, 2011.
120
Bibliography
[70] A. King and I. Phillips. The In vitro activity of daptomycin against 514 gram-positive
aerobic clinical isolates. J Antimicrob Chemother, 48(2):219, 2001.
[71] C.W. Knapp, J. Dolfing, P.A.I. Ehlert, and D.W. Graham. Evidence of increasing an-
tibiotic resistance gene abundances in archived soils since 1940. Environ. Sci. Technol.,
44(2):580–587, 2009.
[72] WN Konings, A. Bisschop, M. Veenhuis, and CA Vermeulen. New procedure for the
isolation of membrane vesicles of Bacillus subtilis and an electron microscopy study of
their ultrastructure. J Bacteriol, 116(3):1456–1465, 1973.
[73] F. Kopp, J. Grünewald, C. Mahlert, and M.A. Marahiel. Chemoenzymatic design of
acidic lipopeptide hybrids: new insights into the structure-activity relationship of dapto-
mycin and a54145. Biochemistry, 45(35):10474–10481, 2006.
[74] C. Krause, J. Kirschbaum, G. Jung, and H. Brückner. Sequence diversity of the peptaibol
antibiotic suzukacillin-a from the mold trichoderma viride. J Pept Sci, 12(5):321–327,
2006.
[75] AJ Kreuzman, RL Hodges, JR Swartling, TE Pohl, SK Ghag, PJ Baker, D. McGilvray,
and WK Yeh. Membrane-associated echinocandin b deacylase of actinoplanes utahen-
sis: purification, characterization, heterologous cloning and enzymatic deacylation re-
action. J. Ind. Microbiol. Biotechnol., 24(3):173–180, 2000.
[76] Alain Laederach, Amy H Andreotti, and D. Bruce Fulton. Solution and micelle-bound
structures of tachyplesin i and its active aromatic linear derivatives. Biochemistry,
41(41):12359–12368, Oct 2002.
[77] J.H. Lakey and M. Ptak. Fluorescence indicates a calcium-dependent interaction be-




[78] J. Lakowicz. Principles of fluorescence spectroscopy. Second Edition, Springer, 1999.
[79] D. Lancet and I. Pecht. Spectroscopic and immunochemical studies with nitrobenzoxa-
diazolealanine, a fluorescent dinitrophenyl analog. Biochemistry, 16(23):5150–5157,
1977.
[80] Y. Le Loir, F. Baron, M. Gautier, et al. Staphylococcus aureus and food poisoning.
Genet Mol Res, 2(1):63–76, 2003.
[81] Chauncey D Leake. The old egyptian medical papyri. Logan Clendening lectures on the
history and philosophy of medicine, second series. University of Kansas Press, 1952.
[82] M. Lipsitch, R.S. Singer, and B.R. Levin. Antibiotics in agriculture: When is it time to
close the barn door? Proc Natl Acad Sci U S A, 99(9):5752, 2002.
[83] D.M. Livermore. Future directions with daptomycin. J Antimicrob Chemother, 62(suppl
3):iii41–iii49, 2008.
[84] N.C. Lloyd, H.W. Morgan, B.K. Nicholson, and R.S. Ronimus. The composition
of ehrlich’s salvarsan: Resolution of a century-old debate. Angew. Chem. Int. Ed.,
44(6):941–944, 2005.
[85] J.K. Long, T.K. Choueiri, G.S. Hall, R.K. Avery, and M.A. Sekeres. Daptomycin-
resistant enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin
Proc, 80:1215–1216, 2005.
[86] C.S. Lopez, H. Heras, H. Garda, S. Ruzal, C. Sanchez-Rivas, and E. Rivas. Biochemical
and biophysical studies of Bacillus subtilis envelopes under hyperosmotic stress. Int J
Food Microbiol, 55(1-3):137–142, 2000.
[87] L. Luzzatto, D. Apirion, and D. Schlessinger. Mechanism of action of streptomycin in e.
coli: interruption of the ribosome cycle at the initiation of protein synthesis. Proc Natl
Acad Sci U S A, 60(3):873, 1968.
122
Bibliography
[88] M. Madigan, J. Martinko, P. Dunlap, and D. Clark. Brock Biology of Microorganisms.
Pearson Benjamin Cummings, twelfth edition edition, 2009.
[89] C. Mahlert, F. Kopp, J. Thirlway, J. Micklefield, and M.A. Marahiel. Stereospecific
enzymatic transformation of α-ketoglutarate to (2 s, 3 r)-3-methyl glutamate during
acidic lipopeptide biosynthesis. J. Am. Chem. Soc., 129(39):12011–12018, 2007.
[90] J. Martens-Lobenhoffer, J.T. Kielstein, C. Oye, and S.M. Bode-B
"oger. Validated high performance liquid chromatography-uv detection method for the
determination of daptomycin in human plasma. J Chromatogr, B: Anal Technol Biomed
Life Sci, 875(2):546–550, 2008.
[91] WJ Martone, KC Lindfield, and DE Katz. Outpatient parenteral antibiotic therapy with
daptomycin: insights from a patient registry. International journal of clinical practice,
62(8):1183–1187, 2008.
[92] C.T.M. Mascio, J.D. Alder, and J.A. Silverman. Bactericidal action of daptomycin
against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob
Agents Chemother, 51(12):4255–4260, 2007.
[93] K. Matsuzaki. Why and how are peptide-lipid interactions utilized for self-defense? ma-
gainins and tachyplesins as archetypes. Biochim Biophys Acta, 1462(1-2):1–10, 1999.
[94] LD Mayer, MJ Hope, and PR Cullis. Vesicles of variable sizes produced by a rapid
extrusion procedure. Biochim Biophys Acta, 858(1):161–168, 1986.
[95] J.B. McCormick. Epidemiology of emerging/re-emerging antimicrobial-resistant bacte-
rial pathogens. Curr Opin Microbiol, 1(1):125–129, 1998.
[96] Å. Melhus and I. Tjernberg. First documented isolation of vancomycin-resistant entero-
coccus faecium in sweden. Scand J Infect Dis, 28(2):191–193, 1996.
123
Bibliography
[97] V. Miao, M.F. Coëffet-Le Gal, K. Nguyen, P. Brian, J. Penn, A. Whiting, J. Steele,
D. Kau, S. Martin, R. Ford, et al. Genetic engineering in streptomyces roseosporus to
produce hybrid lipopeptide antibiotics. Chem Biol, 13(3):269–276, 2006.
[98] V. Miao, M.F. Coëffet-LeGal, P. Brian, R. Brost, J. Penn, A. Whiting, S. Martin, R. Ford,
I. Parr, M. Bouchard, et al. Daptomycin biosynthesis in streptomyces roseosporus:
cloning and analysis of the gene cluster and revision of peptide stereochemistry. Mi-
crobiology, 151(5):1507–1523, 2005.
[99] A.J. Moyer and R.D. Coghill. Penicillin: Viii. production of penicillin in surface cul-
tures. J Bacteriol, 51(1):57, 1946.
[100] J.K. Muraih, J. Harris, S.D. Taylor, and M. Palmer. Characterization of daptomycin
oligomerization with perylene excimer fluorescence: Stoichiometric binding of phos-
phatidylglycerol triggers oligomer formation. Biochim Biophys Acta, 1818(3):673–678,
2012.
[101] J.K. Muraih and M. Palmer. Estimation of the subunit stoichiometry of the membrane-
associated daptomycin oligomer by fret. Biochim Biophys Acta, 2012.
[102] J.K. Muraih, A. Pearson, J. Silverman, and M. Palmer. Oligomerization of daptomycin
on membranes. Biochim Biophys Acta, 1808(4):1154–1160, 2011.
[103] R. Nagaraj and P. Balaram. Membrane modifying linear polypeptide antibiotics. Proc
Natl Acad Sci India, pages 199–218, 1980.
[104] K.T. Nguyen, X. He, D.C. Alexander, C. Li, J.Q. Gu, C. Mascio, A. Van Praagh,
L. Mortin, M. Chu, J.A. Silverman, et al. Genetically engineered lipopeptide antibi-




[105] K.T. Nguyen, D. Ritz, J.Q. Gu, D. Alexander, M. Chu, V. Miao, P. Brian, and R.H. Baltz.
Combinatorial biosynthesis of novel antibiotics related to daptomycin. Proc. Natl. Acad.
Sci., 103(46):17462–17467, 2006.
[106] R. Novak, B. Henriques, E. Charpentier, S. Normark, and E. Tuomanen. Emergence of
vancomycin tolerance in streptococcus pneumoniae. Nature, 399(6736):590–593, 1999.
[107] T.F. O￿Brien et al. Resistance of bacteria to antibacterial agents: report of task force 2.
Rev Infect Dis, 9(Supplement 3):S244, 1987.
[108] K.L. Palmer, A. Daniel, C. Hardy, J. Silverman, and M.S. Gilmore. Genetic basis for
daptomycin resistance in enterococci. Antimicrob Agents Chemother, 55(7):3345–3356,
2011.
[109] M. Palmer, A. Chan, T. Dieckmann, and J. Honek. Biochemical Pharmacology. Wiley
& Sons, first edition edition, 2012.
[110] N. Panchuk-Voloshina, R.P. Haugland, J. Bishop-Stewart, M.K. Bhalgat, P.J. Millard,
F. Mao, W.Y. Leung, and R.P. Haugland. Alexa dyes, a series of new fluorescent
dyes that yield exceptionally bright, photostable conjugates. J Histochem Cytochem,
47(9):1179, 1999.
[111] S. Pestka. Inhibitors of ribosome functions. Annual Reviews in Microbiology,
25(1):487–562, 1971.
[112] J. Pogliano, N. Pogliano, and J. Silverman. Daptomycin mediated reorganization of
membrane architecture causes mislocalization of essential cell division proteins. J Bac-
teriol, 2012.
[113] L. Prescott, J. Harley, and D. Klein. Microbiology. McGrawHill, Higher Education,
sixth edition edition, 2005.
125
Bibliography
[114] W. G. Prowse, A. D. Kline, M. A. Skelton, and R. J. Loncharich. Conformation of
a82846b, a glycopeptide antibiotic, complexed with its cell wall fragment: an asymmet-
ric homodimer determined using nmr spectroscopy. Biochemistry, 34(29):9632–9644,
Jul 1995.
[115] L. Robbel and M.A. Marahiel. Daptomycin, a bacterial lipopeptide synthesized by a
nonribosomal machinery. J. Biol. Chem., 285(36):27501–27508, 2010.
[116] Evelina Rubinchik, Dominique Dugourd, Teresa Algara, Christopher Pasetka, and
H. David Friedland. Antimicrobial and antifungal activities of a novel cationic antimi-
crobial peptide, omiganan, in experimental skin colonisation models. Int J Antimicrob
Agents, 34(5):457–461, Nov 2009.
[117] M.J. Rybak, E. Hershberger, T. Moldovan, and R.G. Grucz. In vitro activities of
daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci
and enterococci, including vancomycin-intermediate and-resistant strains. Antimicrob
Agents Chemother, 44(4):1062, 2000.
[118] A. Schatz, E. Bugie, and S.A. Waksman. Streptomycin, a substance exhibiting antibi-
otic activity against gram-positive and gramnegative bacteria. Proc Soc Exp Biol Med,
55:66–69, 1944.
[119] T. Schneider, K. Gries, M. Josten, I. Wiedemann, S. Pelzer, H. Labischinski, and
H.G. Sahl. The lipopeptide antibiotic friulimicin b inhibits cell wall biosynthesis
through complex formation with bactoprenol phosphate. Antimicrob Agents Chemother,
53(4):1610–1618, 2009.




[121] A.F. Shorr, M.J. Kunkel, and M. Kollef. Linezolid versus vancomycin for Staphy-
lococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob
Chemother, 56(5):923–929, 2005.
[122] S.A. Sieber and M.A. Marahiel. Molecular mechanisms underlying nonribosomal pep-
tide synthesis: approaches to new antibiotics. Chem Rev, 105(2):715–738, 2005.
[123] J. Siedlecki, J. Hill, I. Parr, X. Yu, M. Morytko, Y. Zhang, J. Silverman, N. Controneo,
V. Laganas, T. Li, et al. Array synthesis of novel lipodepsipeptide. Bioorg Med Chem
Lett, 13(23):4245–4249, 2003.
[124] J.A. Silverman, L.I. Mortin, A.D.G. VanPraagh, T. Li, and J. Alder. Inhibition of dap-
tomycin by pulmonary surfactant: In vitro modeling and clinical impact. J Infect Dis,
191(12):2149, 2005.
[125] J.A. Silverman, N.G. Perlmutter, and H.M. Shapiro. Correlation of daptomycin bac-
tericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob
Agents Chemother, 47(8):2538–2544, 2003.
[126] A. Srinivasan, J.D. Dick, and T.M. Perl. Vancomycin resistance in staphylococci. Clin
Microbiol Rev, 15(3):430–438, 2002.
[127] J.N. Steenbergen, J. Alder, G.M. Thorne, and F.P. Tally. Daptomycin: a lipopeptide
antibiotic for the treatment of serious gram-positive infections. J Antimicrob Chemother,
55(3):283–288, 2005.
[128] S.K. Straus and R.E.W. Hancock. Mode of action of the new antibiotic for gram-positive
pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopep-
tides. Biochim Biophys Acta, 1758(9):1215–1223, 2006.
127
Bibliography
[129] J.M. Streit, R.N. Jones, and H.S. Sader. Daptomycin activity and spectrum: a worldwide
sample of 6737 clinical gram-positive organisms. J Antimicrob Chemother, 53(4):669–
674, 2004.
[130] J.L. Strominger, J.T. Park, and R.E. Thompson. Composition of the cell wall of Staphy-
lococcus aureus: its relation to the mechanism of action of penicillin. J. Biol. Chem.,
234(12):3263–3268, 1959.
[131] S.M. Swaney, H. Aoki, M.C. Ganoza, and D.L. Shinabarger. The oxazolidinone line-
zolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother,
42(12):3251–3255, 1998.
[132] F.P. Tally and M.F. DeBruin. Development of daptomycin for gram-positive infections.
J Antimicrob Chemother, 46(4):523–526, 2000.
[133] F.P. Tally, M. Zeckel, M.M. Wasilewski, C. Carini, C.L. Berman, G.L. Drusano, and F.B.
Oleson. Daptomycin: a novel agent for gram-positive infections. Expert Opin Investig
Drugs, 8(8):1223–1238, 1999.
[134] CM Tobin, JM Darville, AM Lovering, and AP MacGowan. An hplc assay for dapto-
mycin in serum. J Antimicrob Chemother, 62(6):1462, 2008.
[135] A. Tomasz. Weapons of microbial drug resistance abound in soil flora. Science,
311(5759):342–343, 2006.
[136] J. Trefouél, J. Trefouél, F. Nitti, and D. Bovet. Activity of p-aminophenylsulfamide in
the experimental streptococcal infections of the mouse and rabbit. C R Seances Soc Biol
Fil, 120:756, 1935.
[137] AE Van den Bogaard, R. Willems, N. London, J. Top, and EE Stobberingh. Antibiotic
resistance of faecal enterococci in poultry, poultry farmers and poultry slaughterers. J
Antimicrob Chemother, 49(3):497, 2002.
128
Bibliography
[138] W. Veatch and L. Stryer. The dimeric nature of the gramicidin a transmembrane channel:
conductance and fluorescence energy transfer studies of hybrid channels. J Mol Biol,
113(1):89–102, 1977.
[139] F.M.E. Wagenlehner, N. Lehn, W. Witte, and K.G. Naber. In vitro activity of daptomy-
cin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin
against enterococci, causing complicated urinary tract infections. Chemotherapy, 51(2-
3):64–69, 2005.
[140] H.C. Wegener, M. Madsen, N. Nielsen, and F.M. Aarestrup. Isolation of vancomycin
resistant enterococcus faecium from food. Int J Food Microbiol, 35(1):57–66, 1997.
[141] M.M. Welling, A. Paulusma-Annema, H.S. Balter, E.K.J. Pauwels, and P.H. Nibbering.
Technetium-99m labelled antimicrobial peptides discriminate between bacterial infec-
tions and sterile inflammations. Eur. J. Nucl. Med. Mol. Imaging, 27(3):292–301, 2000.
[142] R. Welti and M. Glaser. Lipid domains in model and biological membranes. Chem Phys
Lipids, 73(1-2):121–137, 1994.
[143] M. Wittmann, U. Linne, V. Pohlmann, and M.A. Marahiel. Role of dpte and dptf in the
lipidation reaction of daptomycin. FEBS Journal, 275(21):5343–5354, 2008.
[144] PK Wolber and BS Hudson. An analytic solution to the förster energy transfer problem
in two dimensions. Biophys J, 28(2):197–210, 1979.
[145] D. Wolf, P. Domínguez-Cuevas, R.A. Daniel, and T. Mascher. Cell envelope stress re-
sponse in cell wall-deficient l-forms of bacillus subtilis. Antimicrob Agents Chemother,
2012.




[147] M. Zasloff et al. Antimicrobial peptides of multicellular organisms. Nature,
415(6870):389–395, 2002.
130
